netFormulary
 Report : A-Z of formulary items 21/08/2019 04:01:41
[Back]
 
Section Name Details
01.05.03 Vedolizumab 

See NCL treatment pathways for place in therapy in adults (JFC April 2019). Approved for paediatric use (JFC January 2018).

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA. This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA342 June 2015.
14.04 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

Approved as test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH approvals:
    • Not applicable
05.03.01 Abacavir 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine 

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine + Zidovudine Trizivir®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.03 Abatacept 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY.
    • Check MHRA Drug Safety Updates.
    • See links below.
  • RFL approvals:
    • Approved for Rheumatoid Arthritis, in line with NICE guidance.
    • PCT funding approval required.
  • RNOH approvals:
    • Restricted to Rheumatology Consultants ONLY.
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
02.09 Abciximab 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to use in the cardiology cath lab only.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Abiraterone 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. To be prescribed as per NICE guidance
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable to WH
04.10.01 Acamprosate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Requires psychiatrist approval. For use in accordance with NICE CG115.
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.02.03 Acarbose 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Acemetacin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology only.
02.08.02 Acenocoumarol 

Secondary care notes

  • NMUH approvals:
    • Restricted for patients allergic to Warfain only.
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.06 Acetazolamide 

Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension

Secondary care notes

  • NMUH approvals:
    • See link below
    • Immedidate release and modified release formulations are both available
  • RFL approvals:
    • Immediate release only
  • RNOH approvals: 
    • Immediate release only
  • UCLH approvals:
  • WH approvals:
    • Immediate release only
11.08.02 Acetylcholine intra-ocular irrigation Miochol-E®, Miphtel®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
18 Acetylcysteine 

Secondary care notes

  • NMUH approvals:
    • See MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Acetylcysteine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.08.01 Acetylcysteine 5% + Hypromellose 0.35% eye drops Ilube®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.08.01 Acetylcysteine eye drops - preservative free 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Acetylcysteine 5% preservative free drops (10mL) is an unlicensed special and restricted to Ophthalmology.
05.03.02.01 Aciclovir 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.03.03 Aciclovir 3% eye ointment 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.03 Aciclovir 5% cream 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.02 Acitretin 

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Dermatology use only
A5.03.03 Actisorb Silver 220 

Secondary care notes

  • NMUH approvals:
    • We stock 10.5 cm x 10.5 cm. To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
18 Activated charcoal 

Secondary care notes

  • NMUH approvals:
    • Carbomix and Charcodote available
  • RFL approvals:
    • Actidose-Aqua Advance, Carbomix, Charcodote available
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.03 Adalimumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to consultant gastroenterologists 
    • NICE TA187 and TA329 applies
    • JFC (Oct 17): Approved for fistulising Crohn's disease in patients not able to receive infliximab.
10.01.03 Adalimumab 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TA)
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Secondary care notes

  • NMUH approvals: 
    • Check MHRA Drug Safety Updates
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below
  • RFL approvals:
    • Prior funding approval required
    • Restricted to Dermatology, Gastroenterology, Paediatric Gastroenterology and Rheumatology
  • RNOH approvals:
    • Restricted to Rheumatology Consultants Only
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
11.99.99.99 Adalimumab 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.03 Adalimumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists for NICE approved indications.
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.06.01 Adapalene 0.1% + Benzoyl peroxide 2.5% gel Epiduo®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved for Dermatology for acne vulgaris
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Prescribing by Consultant Dermatologists only for acne
13.06.01 Adapalene 0.1% cream Differin®

Approved for acne (JFC April 2016)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See indication above
05.03.03.01 Adefovir Dipivoxil 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal BUT IS NOT LISTED IN THE TRUST FORMULARY AS AN ALTERNATIVE NICE APPROVED MEDICINE IS USED.
  • RFL approvals:
    • Restricted to Hepatology/Virology
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.03.02 Adenosine 6mg/2mL injection Adenocor®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.03 Adrenaline Emerade®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.03 Adrenaline EpiPen®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.07.03 Adrenaline 1:10,000 (1 mg/10 ml) 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.03 Adrenaline 1:10,000 (1mg/10ml) 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.04.03 Adrenaline 1:1000  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of epinephrine 1 in 1,000 units Min-I-Jet injection is reserved for treatment of anaphylaxis in children < 15 kg in weight.
A5.02.07 Advadraw  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.02.03 Advazorb Border 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Afatinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • NOT Applicable
08.01.05 Aflibercept Zaltrap®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
    • See MHRA Drug Safety Update
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.08.02 Aflibercept Eylea®

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultant Ophthalmologists ONLY
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • To be prescribed by consultant opthalmologists only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.08.01 Agalsidase Alfa and Beta Fabrazyme®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.08.01 Agalsidase Alfa and Beta Replagal®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Ajmaline 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Cardiologists ONLY.
    • Ajmaline 50mg in 10mL injection - available from 'special-order' manufacturers or specialist importing companies.
    • See link below
  • RFL approvals:
    • Approve for diagnosis of Brugada syndrome (August 2016)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.05.01 Albendazole 

Secondary care notes

  • NMUH approvals:
    • For use for named patients only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.02.02.02 Albumin Solution 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Available via the blood bank
  • RNOH approvals
    • Available from Pathology
  • UCH approvals:
  • WH approvals:
    • Nil
08.02.04 Aldesleukin 

 Approved for

  • Idiopathic CD4 lymphocytopenia (November 2012)

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.02.04 Alemtuzumab Lemtrada®

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.06.02 Alendronic Acid 

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.04 Alfacalcidol One-Alpha®

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Store in refrigerator
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.04.03 Alfentanil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Controlled Drug Requirements
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.01 Alfuzosin immediate release 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.01 Alfuzosin modified release 

Secondary care notes

  • NMUH approvals:
    • Restricted to Urology Department, second line use only.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of alfuzosin is reserved for the Urology Department only
03.04.01 Alimemazine tabs/solution 

Not recommended for any indication - do not prescribe (JFC November 2018)

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.12 Alirocumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.01 Alitretinoin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.01 Alitretinoin 

Alitretinoin for pityriasis rubra pilaris
Evaluation at RFL site only (August 2016)

10.01.04 Allopurinol 

Secondary care notes

  • NMUH approvals:
    • See link(s) below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • First choice for long-term control of gout
  • UCLH approvals:
  • WH approvals:
    • Nil
12.01.03 Almond oil ear drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

09.06.05 Alpha Tocopheryl Acetate 

 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Oral suspension and injection 100mg/2ml kept at the RFH.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.05 Alprostadil Caverject®

GP-Red Red If used for non-SLS indications

Secondary care notes

  • NMUH approvals:
    • Red List Medicine – Hospital Only Prescribing
  • RFL approvals:
    • Restricted to Urology and Endocrinology consultants
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Inj 20 micrograms only
07.04.05 Alprostadil Viridal® Duo

GP-Red Red If used for non-SLS indications

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.04.05 Alprostadil MUSE®

GP-Red Red If used for non-SLS indications

Secondary care notes

  • NMUH approvals:
    • Red List Medicine – Hospital Only Prescribing Restricted to Consultants in Urology and Sexual Health (St. Ann's) use only.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.10.02 Alteplase 

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for use in Pulmonary Embolism (PE).
  • RFL approvals:
    • Restricted to the HAS unit, vascular surgery and neurosurgery (Intra-arterial therapy for basilar artery thrombosis
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • For massive PE and PE causing cardiac arrest
20 Alteplase 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (JFC July 2018)
      • Paget-Schroetter Syndrome
    • Not approved for:
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (JFC July 2018)
  • RNOH approvals
    • Not applicable
  • UCLH:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (UMC June 2018)
      • Upper Limb Central Venous Catheter (CVC) Related Thrombosis as last-line therapy (UMC June 2018)
    • Not approved for:
      • Paget-Schroetter Syndrome- Refer patient to RFH (UMC June 2018)
      • Stent rethrombosis (UMC June 2018)
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (UMC June 2018)
  • WH approvals:
    • Not applicable
21.01 Alteplase 

Alteplase for complicated visceral thrombosis
Evaluation at RFL site only (July 2014)

13.12 Aluminimum chloride 20% Anhydrol Forte®

Secondary care notes

  • NMUH approvals:
    • Suitable for use in children, adults and the elderly. NOT suitable for use in pregnancy and lactation.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.12 Aluminimum chloride 20% Driclor®

Secondary care notes

  • NMUH approvals:
    • Suitable for use in pregnancy and lactation.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.01.01 Aluminimum Hydroxide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Aluminium acetate 8% or 13% ear drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.01.01 Aluminium hydroxide Alu-Cap®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.02.02 Aluminium Hydroxide Alu-Cap®

 

Secondary care notes

  • NMUH approvals:
    • Alu-Cap can be used as a phosphate binding agent in chronic renal failure. The dose is 4 to 20 capsules daily in divided doses depending on the phosphate level of the patient.
  • RFL approvals:
    • Restricted to renal patients only.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Renal patients only
01.01.01 Aluminium hydroxide + Magnesium hydroxide + Simeticone oral suspension Maalox Plus®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.04 Amantadine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiologist approval only
04.09.01 Amantadine Hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.01 Ambrisentan 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Prior funding approval required. Restricted to the treatment of pulmonary hypertension
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Non Applicable
05.01.04 Amikacin 

Secondary care notes

  • NMUH approvals:
    • Restricted to Microbiology approval only
  • RFL approvals:
    • Restricted to Ophthalmology (intracameral); HIV; Haematology; ERCP prophylaxis
    • Microbiology approval required for all other indications
    • See link below
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
11.03.01 Amikacin 1.5% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to Opthalmology (intracameral)
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Intravitrial use - this is an unlicensed special and restricted to Ophthalmology.
24.01 Amikacin 2.5% eye drops 

unlicensedunlicensed

MEH: Bacterial & Mycobacteria keratitis

02.02.03 Amiloride Hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.01.03 Aminophylline Phyllocontin Continus®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.01.03 Aminophylline IV 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.09 Aminosalicylic acid 

Secondary care notes

  • NMUH approvals:
    • Available from 'special order' manufacturers
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.03.02 Amiodarone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.01 Amisulpride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only.
04.03.01 Amitriptyline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral solution available as 25 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.03 Amitriptyline 

First choice agent for neuropathic pain. Refer to the NCL JFC Neuropathic Pain Prescribing Guideline below.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • See link below
    • Oral solution available as 25 mg/5mL 
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.04.02 Amitriptyline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.06.02 Amlodipine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.02 Amorolfine 5% nail lacquer 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted antimicrobial agent.
    • Only the nail lacquer is available at The Royal Free Hospital
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.01.03 Amoxicillin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
05.02 Amphotericin Fungizone®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • ???Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • Approved for:
      • Cryptococcosis – treatment (Restricted to Microbiology approval)
      • Serious fungal infections (Restricted to Microbiology approval for intraventricular disease)
  • WH approvals:
    • Not applicable
05.02 Amphotericin AmBisome®

Secondary care notes

  • NMUH approvals:
    • As per Trust Guidelines
  • RFL approvals:
    • ???Not applicable
  • RNOH approvals
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
11.03.02 Amphotericin 0.15% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to ophthalmology
09.01.04 Anagrelide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • See links below
  • WH approvals:
    • Nil
20 Anakinra 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved for Familial Mediterranean Fever, Pericarditis and DIRA (RFL only; JFC May 2016)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Anakinra 

Approved for gout for patients who are hospitalised and refractory to all other treatments. The usual dose is 100 mg daily subcutaneously for 3 days (JFC September 2014) 

Secondary care notes

  • NMUH approvals:
    • To be prescribed/ recommended by Rheumatology Consultants ONLY
    • Anakinra has been approved for gout. This is an unlicensed indication and the recommended dose is 100mg by subcutaneous injection ONCE a day for 3 days.
    • Check MHRA Drug Safety Updates
  • RFL approvals:
  • RNOH approvals:
    • Restricted to Rheumatology Consultants ONLY.
    • Unlicensed for the treatment of gout, 100mg daily for 3 days
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology Consultants ONLY
20 Anakinra 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approval for chronic Granulomatous Disease (January 2013)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.01 Anastrozole 

Secondary care notes

  • NMUH approvals:
    • Restricted to Oncology department use only.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.02.04 Anidulafungin 

Approved for invasive candidiasis, subject to local Antimicrobial Committee approval (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
12.03.01 Antacid + Oxetacaine oral suspension 

Approved for oral mucositis post radiotherapy (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • For oral mucositis and oesophageal lesions following radiotherapy. 
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
14.05.03 Anti-D (Rh0) Immunoglobulin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary.
    • It is available via the blood bank
  • RFL approvals:
    • Not available through pharmacy - obtain from the blood bank
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Available from Haematology (Ext 5035)
01.07.02 Anusol-HC® 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Ointment and suppositories both stocked
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Ointment containing hydrocortisone 0.25%. Suppositories containing hydrocortisone acetate 10 mg
21.02 Apalutamide (free of charge) 

Patient-access scheme approved for non-metastatic castration resistant prostate cancer (JFC May 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.02 Apixaban 

See NICE TA for eligibity criteria

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA Drug Safety Update
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.
04.09.01 Apomorphine 

Secondary care notes

  • NMUH approvals:
    • Non-formulary
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.08.02 Apraclonidine ophthalmic solution Iopidine®

Secondary care notes

  • NMUH approvals:
    • Apraclonidine 0.5% used short-term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by another drug
    • See link below   
  • RFL approvals:
    • 1% restricted to Opthalmology
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Apraclonidine 1% preservative free is restricted to Ophthalmology
10.01.03 Apremilast 

Approved for:

  • Psoriatic Arthritis (PsA; see NICE TA)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Rheumatology Consultants ONLY
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
13.05.03 Apremilast 

 Secondary care notes

  • NMUH approvals: 
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.06 Aprepitant 

Secondary care notes

  • NMUH approvals:
    • Restricted to Oncology Consultants only
  • RFL approvals:
    • Restricted to oncology and haematology only.
  • RNOH approvals
    • Restricted for severe emetogenesis.
    • Restricted to Dr Kofi Agyare
  • UCLH approvals:
  • WH approvals:
    • Reserved for the prophylaxis of nausea & vomiting associated with cisplatin (CINV)

 

A5.02.04 Aquacel  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 15 cm * 15 cm(5)
13.02.01 Aquadrate® cream Urea 10%

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01.01 Aqueous Cream BP 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
22.02 Aqueous cream BP 

 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates.
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.03 Arachis Oil Enema 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Requires gastroenterologist approval
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.01 Argatroban 

Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)

Secondary care notes

  • NMUH approval:
    • Not applicable
  • RFL approval:
    • Not applicable
  • RNOH approval:
    • Restricted Item Requires Haematologist approval. See restriction above.
  • UCLH approval:
    • Restricted Item Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
  • WH approval:
    • Not applicable
06.05.02 Argipressin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Store in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.02.01 Aripiprazole 

Intramuscular formulation (7.5mg/1mL) is approved for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder when oral therapy is not appropriate and where IM haloperidol is not recommended. (JFC January 2019)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but NOT routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
    • See links below
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Initiation with Psychiatry advice only
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
08.01.05 Arsenic Trioxide 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Prior funding approval required
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
05.04.01 Artemether + Lumefantrine 

Secondary care notes

  • NMUH approvals:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • First line for uncomplicated falciparum malaria, chloroquine-resistant non-falciparum malaria, and PO step down from IV artesunate
    • See link below
20 Artesunate 

Approved for severe falciparum malaria (November 2015) 

Secondary care notes

  • NMUH approvals:
    • To be used on the recommendation of the Infectious Diseases Team or Microbiology according to the NMUHT malaria guidelines.
    • See link below
    • Available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.03 Ascorbic Acid Vitamin C

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Acidification may prevent encrustation of indwelling catheters, excess mucus formation in bladder augmentation and urinary tract infections. Many patients find high dose ascorbic acid unpalatable and may prefer to take cranberry juice drinks that are now widely available in the high street.
09.06.03 Ascorbic Acid 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Ascorbic acid injection not kept at the RFH; ascorbic acid 500mg is a component of Pabrinex.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.03.03 Askina Calgitrol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Use restricted to Tissue Viability Nurse (TVN) specialist
02.09 Aspirin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.01 Aspirin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Atazanavir 

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per BHIVA Guidelines by HIV team only
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Atazanavir + cobicistat Evotaz®

Secondary care notes

  • NMUH approvals:
    • To be initiated by Consultants in HIV Medicine only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.04 Atenolol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Atenolol injection restricted to cardiology and ITU only.
  • RNOH approvals
    • Tablets available. Oral syrup available as 5 mg/mL
  • UCLH approvals:
  • WH approvals:
    • Tabs 50 mg, 100 mg; Syrup 25 mg/5 ml
08.01.05 Atezolizumab  

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA 520
04.04 Atomoxetine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to the Child & Adolescent Mental Health Service only  
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As per NICE TA98 / CG87
02.12 Atorvastatin 

Secondary care notes

  • NMUH approvals:
    • See NCL JFC Statins Guideline
  • RFL approvals:
    • Use is restricted to HIV, Renal, and lipid clinic patients, as well as suspected simvastatin intolerance and drug interactions. Statin prescribing
  • RNOH approvals
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Nil
07.01.03 Atosiban 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • See links below
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Atosiban is to be used only in accordance with protocol
05.04.08 Atovaquone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Microbiology/ID approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Microbiology use only
05.04.01 Atovaquone + proguanil 

Secondary care notes

  • NMUH approvals:
    • To be used as per the NMUHT Malaria Guidelines
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.05 Atracurium besilate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Store in refrigerator 
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.01.01 Atrauman  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A5.03.03 Atrauman AG 

Secondary care notes

  • NMUH approvals:
    • 10cm x 10 cm is available on the recommendation of the Tissue Viability Nurse only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.02 Atropine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.03 Atropine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.05 Atropine eye drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Atropine 0.5% eye drops are not kept.
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Eye-drops 0.5% not available
11.05 Atropine eye drops - single use 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.03 Atropine Minijet® 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01.01 Aveeno® Bath Oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

#Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

13.02.01 Aveeno® cream 

Secondary care notes

  • NMUH approvals:
    • Not applicable 
  • RFL approvals: 
    • Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.04.05 Aviptadil + phentolamine Invicorp®

Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017)

Secondary care notes

  • NMUH approvals:
    • To be prescribed by Urology Consultants ONLY. To be used as a second line option after treatment failure or intolerance with oral PDE5i (tadalafil or sildenafil) and intracavernosal/ urethral alprostadil.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Approved by NCL as 2nd line treatment for erectile dysfuntion if alprostadil fails (JFC November 2016)
08.01.05 Axitinib 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.01.03 Azacitidine 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Approved for Haematology for MDS, CMML and AML only
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.05.03 Azathioprine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • FBC and LFT monitoring is required.
01.05.03 Azathioprine 

Approved for autoimmune hepatitis (JFC February 2018)

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
    • Nil
  • RNOH approvals
  • UCLH approvals:
  • WH approvals:
    • Specialist initiation, continuation in primary care
08.02.01 Azathioprine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Azathioprine should be initiated only by the Gastroenterology team for difficult cases. Regular monitoring of FBC and LFTs is required.
10.01.03 Azathioprine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.03 Azathioprine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.03 Azathioprine 

Approved for Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP), Recurrent apthous stomatitis (RAS), Oral lichen planus (OLP), Oral Crohn’s disease (OCD) (JFC June 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • Not applicable
13.06.01 Azelaic acid 20% cream Skinoren®

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.02.01 Azelastine + Fluticasone nasal spray Dymista®

Approved for allergic rhinitis when 1st line betamethasone monotherapy and 2nd line fluticasone monotherapy have failed (JFC September 2015)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Approved for the indication outlined above
12.02.01 Azelastine nasal spray Rhinolast®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to the allergy clinic only
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • The use of azelastine hydrochloride nasal spray is restricted to ENT department only
05.01.05 Azithromycin tabs/caps/suspension 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Marlborough OPD; Obs & Gynae (TOP); Renal transplant
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Oral suspension available as 200 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Suspension is reserved for Paediatric and Neonatal use only
24.01 Azithromyin 1.5% single use eye drops 

MEH: Ocular Chlamydia infections; blepharitis

05.01.02.03 Aztreonam 

Secondary care notes

  • NMUH approvals:
    • Consultant Microbiologist recommendation only
  • RFL approvals:
    • Microbiology approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.02.02 Baclofen Intrathecal 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Unlicensed - Intrathecal baclofen 1000 micrograms/mL, 2000 micorgrams/mL and 3000 micrograms/mL are unlicensed products
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.02.02 Baclofen oral 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Oral liquid available as 5 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
13.02.01.01 Balneum® bath oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 Balneum® cream Urea 5%

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01.01 Balneum® Plus bath oil 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Dermatology use ONLY
10.01.03 Baricitinib 

Approved for:

  • Rheumatoid arthritis (see NICE TA)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Rheumatology Consultants Only
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
08.02.02 Basiliximab 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but service is not offered at NMUH.
    • Check MHRA Drug Safety Alerts
  • RFL approvals:
    • Prior funding required for treatment of lymphoma with radiolabelled basiliximab Approved for Renal transplant patients.
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.02.04 BCG bladder instillation ImmuCyst®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
14.04 BCG diagnostic agent - Intradermal injection 

Secondary care notes

  • NMUH approvals:
    • Tuberculin Purified Protein Derivative (PPD)
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Tuberculin PPD SSI is an unlicensed product
14.04 BCG vaccine - Intradermal injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • BCG Vaccine SSI is an unlicensed product
12.02.01 Beclometasone dipropionate 50mcg/spray nasal spray 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.02 Beclometasone dipropionate inhaler Clenil Modulite®

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH approvals:
  • WH approvals:
    • First choice
    • CFC-free beclometasone inhalers are not equipotent and should be prescribed by brand name
    • Inhaler 50 micrograms, 100 micrograms, 200 micrograms, 250 micrograms/metered inhalation ONLY
03.02 Beclometasone dipropionate inhaler Qvar®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Restricted for continuation of treatment. Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH approvals:
  • WH approvals:
    • Turbohalers, Accuhalers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • Inhaler CFC-Free 50 micrograms, 100 micrograms/metered inhalation (Qvar) & Qvar Autohaler 50 micrograms, 100 micrograms, /metered inhalation ONLY
03.02 Beclometasone diproponate + Formoterol inhaler Fostair®

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Fostair should only be supplied when prescribed by, or on the recommendation of, the Respiratory Team. This is to ensure that it is prescribed appropriately.
05.01.09 Bedaquiline 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH approvals:
    • As above
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

Secondary care notes

  • NMUH approvals:
    • Not Applicable.
    • This medicine has a positive NICE Technology Appraisal, however, VENOM IMMUNOTHERAPY SERVICE IS NOT PROVIDED AT NMUH. 
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Restricted Item Restricted
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01 Belimumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH - for intiation at specialist centres.
    • See MHRA Drug Safety Update.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE technology appraisal.
    • See link below.
08.01.01 Bendamustine 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Approved for multiple myeloma (January 2013)
    • Approved for Haematology for indolent NHL, PCT funding approval required
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
    • For relapsed multiple myeloma in line with Cancer Drugs Fund only
  • WH approvals:
    • As per NICE TA(s)
02.02.01 Bendroflumethiazide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.01 Benperidol 

Secondary care notes

  • NMUH approvals:
    • Not applicable  
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Benzathine benzylpenicillin 

Secondary care notes

  • NMUH approvals:
    • Used in the treatment of early syphilis and late latent syphilis
    • Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable  
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.10.02 Benzoic Acid Ointment, Compound BP Whitfield's ointment

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.06.01 Benzoyl peroxide - Topical PanOxyl®

 

Secondary care notes

  • NMUH approvals:
    • Formulary options:
      • Aquagel 2.5% & 10%
      • Gel 5%
    • NON-FORMULARY
      • Aquagel 5% 
      • Cream 5% 
      • Gel 10%
      • Panoxyl wash
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.06.01 Benzoyl peroxide 5% + Clindamycin 1% gel Duac® Once Daily

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Duac gel is restricted to Dermatology
12.03.01 Benzydamine Difflam®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.04 Benzyl Benzoate Application BP 25% 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.01.01 Benzylpenicillin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.06 Betahistine Dihydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.02.02 Betamethasone  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Betamethasone dipropionate 0.05% - Topical Diprosone®

Secondary care notes

  • NMUH approvals:
    • Diprosone cream and Diprosone ointment are FORMULARY.
    • Diprosone lotion is NON-FORMULARY.
  • RFL approvals:
    • ONLY ointment available at Royal Free Hospital
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Betamethasone dipropionate 0.05% + Salicylic acid 3% - Topical Diprosalic®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Betamethasone dipropionate 0.064% + Clotrimazole 1% - Topical Lotriderm®

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology department use ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.04.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Ophthalmology
12.01.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

Secondary care notes

  • NMUH approvals:
    •  Nil
  • RFL approvals:
    •  Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil

 

12.02.03 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

Secondary care notes

  • NMUH approvals:
    •  Nil
  • RFL approvals:
    •  Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
12.01.01 Betamethasone sodium phosphate 0.1% drops 

Secondary care notes

  • NMUH approvals:
    •  Nil
  • RFL approvals:
    •  Nil
  • RNOH approvals
    • Not applicable 
  • UCLH approvals:
  • WH approvals:
    • Nil
12.02.01 Betamethasone sodium phosphate 0.1% drops 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.04.01 Betamethasone sodium phosphate 0.1% drops, 0.1% ointment 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.01 Betamethasone soluble tablets 

Approved for oral mucosal inflammatory disease (JFC March 2018)

Secondary care notes

  • NMUH approvals:
    •  Nil
  • RFL approvals:
    •  Not applicable
  • RNOH approvals:
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above

 

06.03.02 Betamethasone systemic injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Inj 4 mg/1 ml ONLY
06.03.02 Betamethasone tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Betamethasone valerate 0.025% - Topical Betnovate-RD®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Betamethasone valerate 0.1% - Topical 

Secondary care notes

  • NMUH approvals: 
    • When Betnovate cream or ointment are requested/prescribed, the non-proprietary version, betamethasone valerate 0.1% cream or ointment will be supplied.
    • When Betnovate scalp application is prescribed/requested, Betacap (betametasone valerate 0.1%) scalp application will be supplied.
  • RFL approvals:
    • Only Cream, Ointment and Scalp application available at the Royal Free Hospital
  • RNOH approvals:
    •  Nil
  • UCLH approvals:
  • WH approvals:
    • Nil

 

13.04 Betamethasone valerate 0.1% + Clioquinol 3% - Topical 

Secondary care notes

  • NMUH approvals:
    •  Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Betamethasone valerate 0.1% + Fucidic acid 2% - Topical Fucibet®

 Secondary care notes

  • NMUH approvals:
    • Fucibet cream is FORMULARY
    • Fucibet lipid cream is NON-FORMULARY
  • RFL approvals:
    • ONLY the cream available at the Royal Free Hospital
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Dermatology use ONLY
    • Cream ONLY available
13.04 Betamethasone valerate 0.1% + Neomycin sulphate 0.5% - Topical 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

13.04 Betamethasone valerate 0.1% scalp application Betacap®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Betamethasone valerate 0.12% scalp application Bettamousse®

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.06 Betaxolol 0.5% solution eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approval:
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Bevacizumab 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
11.08.02 Bevacizumab intravitreal injection 

Approved for:

  • Neovascular glaucoma (single-dose intravitreal) as an adjunct to panretinal photocoagulation (January 2017)
  • Pre-operative adjunct to diabetic vitrectomy (MEH only; April 2017)
  • Coats' disease and Familial exudative vitreoretinopathy (FEVR) (November 2015)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved for use in neovascular glaucoma as an adjunct to panretinal photocoagulation
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • Not applicable
08.01.05 Bexarotene 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Prior funding approval required
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
02.12 Bezafibrate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.12 Bezafibrate modified release 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Bicalutamide 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Oncologist and Urologist use only.
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Bicalutamide 150mg is reserved for the treatment of locally advanced prostate cancer where it is important to maintain sexual potency.
11.06 Bimatoprost 0.01% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops Ganfort®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops - preservative free Ganfort®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Combination therapies to be used when compliance/cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Bimatoprost 0.03% eye drops- single use 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Nil
09.08.01 Biotin  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.05 BioXtra® oral gel 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50

First choice biphasic analogue insulin. See NCL guideline for insulin in Type 2 diabetes guideline.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Mix25: Non-formulary
    • Mix50: Formulary
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Mix25: Non-formulary
    • Mix50: Formulary
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 15, Insuman® Comb 25, Insuman® Comb 50

First choice biphasic human insulin. See NCL guideline for insulin in Type 2 diabetes guideline.

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.06.02 Bisacodyl 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Please note: Suppositories 10 mg, Paediatric suppositories 5 mg only
02.04 Bisoprolol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.08.01 Bivalirudin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
  • RFL approvals:
    • Restricted to use in the Cardiology Cath Lab only.
  • RNOH approvals:
    • Restricted Item Restricted
  • UCLH approvals:
  • WH approvals:
    • NICE TA230 applies. Not routinely stocked at WH.
08.01.02 Bleomycin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Boostrix-IPV 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Bortezomib injection 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.01 Bosentan 

Approved for digital ulceration in systemic sclerosis in line with NHSE Clinical Commissioning Policy A13/P/e (May 2015)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • See restrictions on use
    • Prior funding approval required
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.05.01 Bosentan 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Prior funding approval required
    • Restricted to the treatment of pulmonary hypertension
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Bosutinib 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.07.04 Botulinum toxin type A Botox®, Dysport®, Xeomin®

Secondary care notes

  • NMUH approvals:
    • Xeomin brand only
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.04.02 Botulinum Toxin Type A Botox®

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA but service not offered at NMUH.
  • RFL approvals:
    • Headaches and chronic migraine
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.09.03 Botulinum Toxin Type A Botox®, Dysport®, Xeomin®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Dysport (first line) and Botox brands only
    • Restricted 
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.04.02 Botulinum toxin Type A Botox®

Approved for neurogenic bladder dysfunction for patients refractory to oral therapies (JFC January 2013) QUERY FUNDING

 

Secondary care notes

  • NMUH approvals:
    • Botox brand only
    • Restricted to consultants Dr Yoong, Mr Nair and Mr Godbole for use in Overactive Bladder (OAB) only
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • See Botulinum Toxin Management Algorithm Diagram for direction of use
20 Botulinum toxin Type A Botox®, Dysport®, Xeomin®

Approved for Sphincter of Oddi Dysfunction  (JFC January 2013). QUERY funding

Secondary care notes

  • NMUH approvals:
    • Xeomin is formulary when used in the treatment of achalasia (other brands and indications are non-formulary)
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.09.03 Botulinum Toxin Type B NeuroBloc®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Brentuximab vedotin 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA
11.06 Brimonidine 0.2% + Timolol 0.5% eye drops Combigan®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See link below
11.06 Brimonidine 0.2% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not to be used for first-line treatment - see link below
13.06.01 Brimonidine 3 mg/g gel 

Approved for moderate to severe rosacea causing psychological distress or reduced quality of life - initiation by secondary care Dermatologist and continuation in primary care (JFC September 2014)

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Brinzolamide 0.1% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Use in line with NCL guideline below
11.06 Brinzolamide 1% + Timolol 0.5% eye drops Azarga®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.03 Brodalumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
04.09.01 Bromocriptine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07.01 Bromocriptine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • 1mg tablets are non-formulary
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 1st Choice
01.05.02 Budesonide Entocort®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.02 Budesonide Budenofalk®

Approved for active ulcerative colitis limited to the rectum and sigmoid colon as second-line (prednisolone retention enema is the first-line choice) (JFC October 2018).

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted use
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
03.02 Budesonide + Formoterol inhaler Symbicort® Turbohaler

Not approved as the sole inhaler for asthma (SMART), may be used twice daily for asthma (September 2015).

 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.02 Budesonide + Formoterol inhaler DuoResp Spiromax®

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per JFC Asthma / COPD guidelines
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.02.01 Budesonide 100mcg/spray nasal spray 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • 100 microgram on formulary
    • 64 microgram strength only available at the RNTNE
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.02 Budesonide inhaler Pulmicort® Turbohaler

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.02 Budesonide nebuliser suspension 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nebulised budesonide should only be prescribed on the advice of a Consultant Paediatrician or a Respiratory Consultant.
20 Budesonide nebuliser suspension 

Approved as second-line choice (after fluticasone inhaler) for eosinophilic oesophagitis in both adults and children. Dose should be dispersed in viscous suspending agent (e.g. Splenda slurry). Starting dose is 1 mg twice-daily for adults and children > 10 years old, 1 mg once-daily for children < 10 years old; down titrate dose for maintenance dosing (JFC February 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • As above
02.02.02 Bumetanide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
15.02 Bupivacaine  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • INJ 0.25% (25MG/10ML); 0.5% (50MG/10ML) ONLY
15.02 Bupivacaine + Adrenaline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
15.02 Bupivacaine + Fentanyl 

Secondary care notes

  • NMUH approvals:
    • A ready mixed bag of Fentanyl + Bupivicaine is available from Pharmacy
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.02 Bupivacaine + Glucose Marcain Heavy®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Buprenorphine patch '5' and '10' 

Only buprenorphine patch (originally BuTrans) ‘5’ and ‘10’ patches are available. Restricted for patients unable to take oral opioids due to swallowing difficulties / short bowel AND requiring a lower dose transdermal opioid dose than the 12 micrograms fentanyl patch (JFC March 2015)

Secondary care notes

  • NMUH approvals:
    • See restriction above
  • RFL approvals:
  • RNOH approvals:
    • See restriction above
  • UCLH approvals:
  • WH approvals:
    • See restriction above
04.07.02 Buprenorphine sublingual tablets 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.10.03 Buprenorphine sublingual tablets  

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
    • For continuation ONLY
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.10.02 Bupropion 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.02 Buserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to consultant gynaecologists only.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.02 Buserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to consultant gynaecologists only.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Buserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.01.01 Busulfan infusion 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
    • Approved for multiple myeloma (January 2013)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
    • Approved for conditioning prior to haematopoietic progenitor cell transplantation
  • WH approvals:
    • Nil
08.01.05 Cabazitaxel 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Prior funding approval required via CDF
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable to WH
04.09.01 Cabergoline 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.01 Cabergoline 

Secondary care notes

  • NMUH approvals:
    • Restricted to Obs & Gynae Consultant use only
  • RFL approvals:
    • Restricted to Endocrinology and Gynaecology.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Cabergoline is reserved for use by Dr Moult and for suppression of lactation
08.01.05 Cabozantinib caps Cometriq®

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • As per NICE guidance for the treatment of medullary thyroid cancer
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Cabozantinib tabs Cabometyx®

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • As per NICE guidance for the treatment of renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable to WH
21.01 Cacicol 

Non-healing corneal ulcers/ persistent epithelial defects. 
Under evaluation at MEH only (restricted to corneal eye disease service only, April 2017)

13.03 Calamine lotion 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Lotion BP 100 ml only
13.05.02 Calcipotriol 50mcg/g - Topical Dovonex®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatology only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Calcipotriol scalp application is restricted to Dermatology use only
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical Dovobet®

Secondary care notes

  • NMUH approvals:
    • Restricted to consultant Dermatologists ONLY
  • RFL approvals:
    • Restricted to Dermatology ONLY
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For patients who fail separate topical steroid + vitamin D2 (e.g. calcipotriol)
    • Dovobet ointment restricted to Dermatology use ONLY
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical foam Enstilar®

 

Approved after failure of combined topical steroid + vitamin D2 (e.g. Dovobet ointment) (JFC May 2017)

Secondary care notes

  • NMUH approvals:
    • For Trunk & Limb psoriasis in patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
06.06.01 Calcitonin (salmon) 

Secondary care notes

  • NMUH approvals:
    • See link below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Only calcitonin injections kept at RFH
  • RNOH approvals:
    • Restricted
    • Store in a refrigerator
    • Allow to reach room temperature before subcutaneous or intramuscular use.
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.02 Calcitriol 3mcg/g - Topical Silkis®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Calcitriol ointment is restricted to Dermatology use only
09.05.01.02 Calcitriol injection 

Secondary care notes

  • RFL approvals:
    • Approved for percutaneous injection into the parathyroid gland for hyperparathyroidism if intolerant or unresponsive to oral therapy (November 2013)
09.06.04 Calcitriol oral 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.02.02 Calcium Acetate Phosex®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to renal patients only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.06.04 Calcium and Ergocalciferol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.01.01 Calcium carbonate Cacit®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • WH approvals:
    • Not applicable
09.05.01.01 Calcium carbonate Calcichew®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.01.01 Calcium Carbonate Adcal®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.02.02 Calcium Carbonate Calcichew®

Secondary care notes

  • NMUH approvals:
    • Calcichew is available on the Formulary for the management of hyperphosphotaemia in renal patients
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.02.02 Calcium Carbonate Adcal®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.02.02 Calcium Carbonate Calcium-500®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to renal patients only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.01.01 Calcium Chloride injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01 Calcium Folinate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.01.01 Calcium Gluconate 10% injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.01.01 Calcium Gluconate effervescent tablets 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 Calmurid® cream Urea 10%

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A2.04.01.02 Calogen 

Secondary care notes

  • NMUH approvals:
    • For disease-related malnutrition, malabsorption states or other conditions requiring fortification with a high-fat supplement with or without fluid and electrolyte restrictions Fat supplement without any electrolytes. Used for when protein, fluid or electrolytes restricted. Tolerating low volume of food. Can be used as a “medicinal dose” in combination with another supplement which is providing protein and calories
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.02.03 Canagliflozin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL approvals:
    • Restricted to Endocrinology
  • RNOH approvals
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.05.02 Candesartan 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Restricted Item Restricted
  • UCLH approvals:
  • WH approvals:
    • 1st choice A2RA/ARB for heart failure
02.09 Cangrelor 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Primary percutaneous coronary intervention (PPCI) who are intubated and cannot tolerate oral antiplatelets (JFC October 2017)
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • Not applicable
08.01.03 Capecitabine 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.02 Caplacizumab injection (free of charge) 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • Approved for thrombotic thrombocytopenia while available under a manufacturer-funded patient access scheme only (UCLH only; JFC September 2018)
  • WH approvals:
    • Not applicable
05.01.09 Capreomycin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Microbiology/ ID approval only
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted to TB clinic or as per Microbiology advice
10.03.02 Capsaicin cream  

Secondary care notes

  • NMUH approvals: 
    • 0.025% NON FORMULARY
    • 0.075% restricted to pain clinic use ONLY
  • RFL approvals: 
    • 0.025% NON FORMULARY
    • 0.075% strength kept at the RFH ONLY
  • RNOH approvals:
    • 0.025% restricted for use in accordance with the NICE guideline for osteoarthritis
    • See link(s) below
    • 0.075% NON FORMULARY
  • UCLH approvals:
  • WH approvals:
    • 0.025% restricted to the Rheumatology team. This strength of capsaicin cream is indicated for osteoarthritis only.
    • 0.075% restricted to pain clinic ONLY
10.03.02 Capsaicin patch 

JFC approved for neuropathic pain (January 2013)

Secondary care notes

  • NMUH approvals:
    • Not applicable  
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Restricted to named Consultants within the Chronic Pain team (Dr Roxy Zarnegar and Dr Tacson Fernandez) ONLY in accordance with DTC approval
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.05.05.01 Captopril 

Secondary care notes

  • NMUH approvals:
    • Only used for test dose
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • The use of Captopril is reserved for situations where a short- acting preparation is necessary.
04.02.03 Carbamazepine Mania

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.03 Carbamazepine 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • ???
  • RNOH approvals:
    • Oral liquid available as 100 mg/5mL 
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.01 Carbamazepine immediate release 

Prescribe by brand when used for epilepsy.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Oral liquid available as 100 mg/5mL 
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.01 Carbamazepine modified release 

Prescribe by brand when used for epilepsy.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.01.01 Carbetocin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
06.02.02 Carbimazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.07 Carbocisteine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Restricted Item Restricted. Capsules available. Oral syrup available as 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Carbocisteine to be initiated by respiratory team only
    • Liquid only available for patients with swallowing difficulties or for enteral feeding tube administration
11.08.01 Carbomers eye gel Viscotears®, GelTears® and others

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Carboplatin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Carboplatin + paclitaxel (CROSS) 

Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • As above
  • WH approvals:
    • Not applicable
07.01.01 Carboprost 

Secondary care notes

  • NMUH approvals:
    • Restricted to Obs and Gynae only. 
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Carfilzomib 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA 457
11.08.01 Carmellose eye drops - single use 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Ophthalmology
12.03.01 Carmellose Sodium Orabase®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.01 Carmustine implant Gliadel®

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Restricted to Neurosurgery
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
02.04 Carvedilol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Carvedilol 

Approved for primary and secondary prevention of variceal bleeding for patients who do not respond to or cannot tolerate propranolol (August 2015)

Secondary care notes

  • NMUH approvals:
    • See restrictions on use
  • RFL approvals:
    • See restrictions on use
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • See restrictions on use
05.02.04 Caspofungin 

Secondary care notes

  • NMUH approvals:
    • Microbiology consultant approval only
  • RFL approvals
    • Restricted to Haematology (in discussion with Microbiology, as per protocol).
    • Microbiology approval required for all other indications.
  • RNOH approvals
    • Microbiology approval only
    • Store in a fridge
  • UCLH approvals:
  • WH approvals:
    • Reserved for prescribing by paediatric consultants only
07.04.04 Catheter Patency Solutions 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.04 Catheter Patency Solutions 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only Sodium Chloride Uro-Tainer M kept at the RFH.
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.02.05 Cavi-Care 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.02.01 Cefalexin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral suspension available as 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.02.01 Cefixime 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine.
  • RFL approvals:
    • Restricted to Marlborough OPD and used for IV/PO switch with Microbiology approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.02.01 Cefotaxime 

Secondary care notes

  • NMUH approvals:
    • Restricted to Microbiology approval only
  • RFL approvals:
    • Restricted to Neonates and Liver unit
    • Microbiology approval required in all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Paediatrics and Neonatal use only
05.01.02.01 Ceftazidime 

Secondary care notes

  • NMUH approvals:
    • Restricted to Microbiology approval only
  • RFL approvals:
    • Restricted to Haematology  
    • Microbiology approval required in all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Ceftazidime + Avibactam  

Approved for the treatment of infections caused by non-MBL carbapenemase-producing aerobic Gram-negative organisms, that have proven susceptibly to ceftazidime-avibactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin, which cannot be used due to resistance or intolerance - Microbiology recommendation only (JFC August 2017)

Secondary care notes

  • NMUH approvals:
    • Microbiology approval only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted antibiotics. Microbiology approval only
11.03.01 Ceftazidime 5% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to ophthalmology
24.01 Ceftazidime 5% eye drops 

unlicensedunlicensed

MEH: Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis

24.01 Ceftazidime 5% eye drops 

unlicensedunlicensed

MEH: Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis

05.01.02 Ceftolozane + tazobactam 

Approved for multi-resistant Gram-negative organisms that have proven susceptibly to ceftolozane-tazobactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin (JFC September 2016)

Secondary care notes

  • NMUH approvals:
    • Microbiology recommendation ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted antibiotics. Microbiology approval only
05.01.02.01 Ceftriaxone 

Secondary care notes

  • NMUH approvals:
    • Restricted to use in paediatrics for sepsis and meningitis
  • RFL approvals:
    • Restricted for use in Meningitis; Brain abscess; Obstetrics; Liver Unit; Pelvic Inflammatory Disease, Paediatrics
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Cefuroxime 

Secondary care notes

  • NMUH approvals:
    • Restricted to Microbiology approval only
    • Injection is formulary
    • Tablets are non-formulary
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.03.01 Cefuroxime 5% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to ophthalmology
24.01 Cefuroxime 5% eye drops 

unlicensedunlicensed

MEH: Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis; blebitis; bleb-related endophthalmitis

11.03.01 Cefuroxime intracameral injection Aprokam®

Approved for prophylaxis post-cataract surgery (June 2013)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Celecoxib 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • For Rheumatology use only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Celiprolol hydrochloride 

Approved for vascular Ehlers-Danlos syndrome (JFC April 2016)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Ceritinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA
10.01.03 Certolizumab pegol 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic arthritis (PsA; see NICE TAs)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines (see links below).
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update.
    • See links below.
  • RFL approvals:
    • Approved for rheumatoid arthritis in line with NICE guidance.
    • PCT funding required.
  • RNOH approvals:
    • Restricted for Rheumatology Consultants ONLY.
    • See links below.
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
03.04.01 Cetirizine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.02.01.01 Cetraben® bath additive 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Dermatology use ONLY
13.02.01 Cetraben® cream 

Cetraben cream, Enopen cream, ExCetra cream, Exmaben cream and Soffen cream all contain Liquid paraffin light 105 mg/g + White soft paraffin 132 mg/g.

Secondary care notes

  • NMUH approvals:
    • Restricted for prescribing in Paediatrics and by Dermatologists
    • Preferred preparation is Enopen Cream
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Cream 50g, 500g ONLY
06.07.02 Cetrorelix 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to haematology for the preservation of female fertility.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable 
08.01.05 Cetuximab 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Updates
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.01.01 Chloral Hydrate 

Secondary care notes

  • NMUH approvals:
    • Chloral Mixture, BP 2000, 500mg/5mL (Unlicensed)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Paediatrics only
    • Chloral hydrate suppositories 25mg & 100mg available
08.01.01 Chlorambucil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.07 Chloramphenicol 

Secondary care notes

  • NMUH approvals:
    • Chloramphenicol capsules are non-formulary
    • To be used as per the Trust guidelines for Management of Acute Bacterial Meningitis 
  • RFL approvals:
    • Systemic use restricted to Neurology; Neurosurgery; Paediatrics
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
11.03.01 Chloramphenicol 0.5% eye drops - Single use drops 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.03.01 Chloramphenicol 0.5% eye drops, 1% eye ointment 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Eye drops 0.5% preservative free 10mL (Moorfields special) also available
12.01.01 Chloramphenicol 5% ear drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.01.02 Chlordiazepoxide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to in-patient use for alcohol detoxification.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.11.02 Chlorhexidine + Alcohol wipes Clinell Alcoholic 2% Chlorhexidine Wipes®

Secondary care notes

  • NMUH approvals:
    • This product is available as individual sachets of 105x105mm in size and comes in boxes of 200.
    • Uses:
      1. Skin antisepsis prior to insertion of peripheral cannulae, or taking blood cultures.
      2. Skin antisepsis prior to taking blood cultures.
      3. Line care: Disinfection of catheter hubs/ports of all IV lines prior to access.
      4. Post insertion line care  (ChloraPrep to be used for skin antisepsis prior to insertion of central line cannulae)
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.11.02 Chlorhexidine 0.015% + Cetrimide 0.15% skin cleaner Tisept®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
12.02.03 Chlorhexidine 0.1% + Neomycin 0.5% cream Naseptin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.04 Chlorhexidine 0.2% mouthwash 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • MRSA screening procedure
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.04 Chlorhexidine 0.2% oral spray 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to community clinic only
12.03.04 Chlorhexidine 1% dental gel 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.11.02 Chlorhexidine skin cleaners 

Secondary care notes

  • NMUH approvals:
    • The following products are available:
      • ChloraPrep®, Hibiscrub® (see link below for MRSA eradication protocol), Hibitane Obstetric® (restricted to obstetrics), Hydrex®, Unisept®
  • RFL approvals:
    • The following products are avaialble:
      • ChloraPrep®, Hibiscrub®, Hibitane Obstetric®, Hydrex®, Unisept®
  • RNOH approvals:
    • Available products:
      • ChloraPrep®, Hibiscrub®
  • UCLH approvals:
  • WH approvals:
    • Available products:
      • Chlorhexidine 0.05%CX Antiseptic Dusting Powder®, Hibiscrub®, Hibitane Obstetric®, Hydrex®
12.01.03 Chlorobutanol 5% + Arachis (peanut) oil ear drops Cerumol®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.02 Chloroprocaine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.04.01 Chloroquine 

Secondary care notes

  • NMUH approvals:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Chloroquine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Chlorothiazide 

Secondary care notes

  • NMUH approvals:
    • For the treatment of chronic hypoglycaemia, heart failure, hypertension and ascites, in children.
    • See the BNF for children for further prescribing information.
    • Chlorothiazide suspension 250mg/5ml, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Chlorothiazide Suspension 250 mg/5 ml (unlicensed product)
03.04.01 Chlorphenamine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Tablets and injection available, Oral syrup available as 2 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.01 Chlorpromazine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
    • Suppositories are not stocked
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Tabs 25 mg, 50 mg, 100 mg. Syrup 25 mg/5ml, 100 mg/5 ml. Injection 50 mg/2ml. Only
04.06 Chlorpromazine 

Secondary care notes

  • NMUH approvals:
    • Nil  
  • RFL approvals:
    • Suppositories are not stocked at RFH
  • RNOH approvals
    • Oral solution available as 25 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.01 Choline Salicylate 8.7% oral gel Bonjela® Adult, Teejel®

Secondary care notes

  • NMUH approvals:
    • Teejel stocked
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • For patients 16 years and above
  • UCLH approvals:
  • WH approvals:
    • Nil
06.05.01 Chorionic Gonadotrophin Choragon®, Pregnyl®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.05.03 Ciclosporin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Ciclosporin is restricted to Consultant Gastroenterologists only
    • FBC, LFT & drug level monitoring required
08.02.02 Ciclosporin Capsorin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.02.02 Ciclosporin Deximune®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.02.02 Ciclosporin Neoral®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant use only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.02.02 Ciclosporin Capimune®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.02.02 Ciclosporin Sandimmun®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.03 Ciclosporin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.03 Ciclosporin 

Approved for:

  • chronic refractory idiopathic urticaria (JFC - January 2015)
  • severe atopic dermatitis (DMARD fact sheet)
  • severe psoriasis (DMARD fact sheet)

 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.99.99.99 Ciclosporin 0.1% eye drops Ikervis®

Approved for ocular inflammatory conditions. See NCL fact sheet. 

 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed Consultant Ophthamologist ONLY
    • See links below
  • RFL approvals
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
    • For initiation by corneal specialists only
  • WH approvals:
    • Restricted to ophthalmology
11.99.99.99 Ciclosporin 0.2% eye ointment 

Approved for ocular inflammatory conditions. See NCL fact sheet. 

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.03.01 Cimetidine 

 Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted Item Restricted: 200mg and 400mg tablets available. The 800mg tablets are not available
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Alternative to ranitidine. Tabs 200 mg, 400 mg.
09.05.01.02 Cinacalcet 

Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
    • Formulary for treatment of Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma - see link below
  • RFL approvals:
    • Under Professor Cunningham's recommendation and approved for endocrinology.
  • RNOH approvals
    • Not applicable
  • WH approvals:
    • For primary hyperparathyroidism in line with NHSE policy 16034/P
    • For secondary hyperparathyroidism in line with NICE TA 117
04.06 Cinnarizine 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.12 Ciprofibrate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.12 Ciprofloxacin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Haematology; HIV; Immunology; Oncology; Malignant otitis externa; Necrotising fascitis; Endopthalmitis; Prophylaxis in SBP and leech therapy; Epidydymo-orchitis; Prostatitis; ERCP prophylaxis
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Oral suspension available as 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
11.03.01 Ciprofloxacin 0.3% eye drops, 0.3% eye ointment 

 Secondary care notes

  • NMUH approvals:
    • Restricted to Ophthalmology department use ONLY.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.05 Cisatracurium 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • The use of cisatracurium is restricted to theatres only.
08.01.05 Cisplatin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.03.03 Citalopram 

Secondary care notes

  • NMUH approvals:
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Tablets available. Oral drops available as 40 mg/mL
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.03 Cladribine 

Secondary care notes

  • NMUH approvals:
    • To be prescribed by the Haematology Team ONLY.
    • Refer to BCSH Guidelines on Hairy Cell Leukaemia
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
05.01.05 Clarithromycin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Microbiologist approval only
    • Oral suspension available as 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.06 Clindamycin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to HIV; Necrotising fasciitis; Endocarditis prophylaxis; Beta-lactam allergy; Aspiration pneumonia; Surgical prophylaxis in Obstetrics and Plastic surgery.
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
13.06.01 Clindamycin 1% topical solution Dalacin T®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatology only
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.02.02 Clindamycin 2% vaginal cream Dalacin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.01 Clobazam 

Secondary care notes

  • NMUH approvals:
    • Clobazam oral suspension is non-formulary
  • RFL approvals:
    • Blacklist restriction except in epilepsy
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Should only be commenced on the recommendation of a Neurologist
13.04 Clobetasol propionate 0.05% - Topical Dermovate®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Clobetasol propionate 0.05% shampoo Etrivex®

Secondary care notes

  • NMUH approvals:
    • For use SECOND LINE in topical treatment of MODERATE SCALP PSORIASIS in adults who have failed treatment with Dermovate 0.05% Scalp Application.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Clobetasol propionate 1 in 4 in White Soft Paraffin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Clobetasol propionate 1 in 4 in White Soft Paraffin 100 g (unlicensed product)
13.04 Clobetasone butyrate 0.05% - Topical Eumovate®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Clobetasone butyrate 0.05% + Oxytetracyline 3% + Nystatin - Topical Trimovate®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
    • Approved for Pruritus ani; Dermatitis - seborrhoeic - infected; Nappy rash; Infected intertrigo; Eczema - infected
  • WH approvals:
    • Nil
08.01.03 Clofarabine 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Resticted
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
05.01.10 Clofazimine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Microbiology/ID approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
04.01.01 Clomethiazole 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.05.01 Clomifene 

GP-Red Red Hospital only prescribing if used for IVF

GP-Grey Red Other indications

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.03.01 Clomipramine Antidepressant

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.03 Clonazepam 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.03 Clonazepam 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Specialist use only
04.08.01 Clonazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Suspension 2 mg/5ml. Suspension should not be administered via PEG tubes as it is incompatible with the polystyrene fittings
02.05.02 Clonidine Hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only 25 microgram tablets and the injection kept at the RFH
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.04.02 Clonidine Hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Clonidine Hydrochloride 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
02.09 Clopidogrel 

See NICE TA for eligibility

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per NICE guidelines - see links below for further details
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.02.02 Clotrimazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only 1% cream, 200mg Pessaries and 500mg Pessaries kept at RFH
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Pessaries available as 200 mg & 500 mg
13.10.02 Clotrimazole 1% - Topical 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Cream 1% only
  • UCLH approvals:
  • WH approvals:
    • Cream 1% 20g, Solution 1% 20mL and Dusting Powder 1% 30g ONLY
12.01.01 Clotrimazole 1% ear drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.01 Clozapine Clozaril®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Psychiatrist use only
    • Monitoring required
    • See links below
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
    • If a patient is admitted on this therapy please ensure that the pharmacy mental health team are aware.
    • Patients being treated in the UK will be registered with CPMS (Clozaril Patient Monitoring Service)
    • See links below
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
21.01 Co‐careldopa 

Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016).

13.09 Coal tar 1% + Coconut oil 1% + Salicylic acid 0.5% shampoo Capasal®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to dermatology patients only
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Cocois®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Sebco®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.02 Coal tar and salicylic acid ointment, BP 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.09 Coal tar extract 5% alcoholic shampoo Alphosyl 2 in 1®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
20 Coal tar in Betamethasone ointment 

Secondary care notes

  • NMUH approvals:
    • To be prescribed by Consultant Dermatologists for the treatment of Psoriasis.
    • Coal Tar 10% in Betamethasone 0.025% Ointment Coal Tar 5% in Betamethasone 0.025% Ointment
    • The above preparations are available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.02.04 Co-amilofruse  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.02.04 Co-amilozide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.01.03 Co-Amoxiclav 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral suspension available as 125/31.25 mg/5mL and 250/62.5 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
04.09.01 Co-Beneldopa immediate release 

Secondary care notes

  • NMUH approvals:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.09.01 Co-Beneldopa modified release 

Secondary care notes

  • NMUH approvals:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Cobicistat 

Second line protease inhibitor booster for HIV for confirmed ritonavir intolerance (March 2016)

Secondary care notes

  • NMUH approvals:
    • To be initiated by Consultants in HIV Medicine only
    • See MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.02.04 Cobimetinib 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.07 Cocaine 4% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • This is an unlicensed special and restricted to Ophthalmology
    • This is a controlled drug
04.07.02 Cocaine Hydrochloride Solution 10% w/v  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted Item Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.09.01 Co-Careldopa immediate release 

Secondary care notes

  • NMUH approvals:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.09.01 Co-Careldopa intestinal gel Duodopa®

Approved for Parkinson's disease in line with NHSE clinical commissioning policy D04/P/e (JFC November 2019).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Prior funding approval required
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.09.01 Co-Careldopa modified release 

Secondary care notes

  • NMUH approvals:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.01 Co-codamol 30/500 Paracetamol + Codeine

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.01 Co-codamol 8/500 Paracetamol + Codeine

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.06.02 Co-Cyprindiol 2000/35 (cyproterone 2mg / ethinylestradiol 35micrograms) Dianette®

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.02 Co-danthramer 

Secondary care notes

  • NMUH approvals:
    • Restricted to terminally ill patients only
  • RFL approvals:
    • Restricted to oncologist and geriatricians
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Because of a potential carcinogenic risk, danthron containing laxatives are indicated only for constipation in the terminally ill. Co-danthramer may cause irritation and excoriation in incontinent patients and may colour the urine red. Please note: Capsules not available. Suspension only.
01.06.02 Co-danthrusate 

Secondary care notes

  • NMUH approvals:
    • Restricted to terminally ill patients only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable 
  • WH approvals:
    • Not applicable
01.04.02 Codeine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Codeine 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted for patients admitted on codeine, requiring further supply.
    • Oral solution available as 15 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
03.09.01 Codeine Linctus BP 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.01 Co-dydramol 10/500 Paracetamol + dihydrocodeine

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.04 Colchicine 

Secondary care notes

  • NMUH approvals:
    • See link(s) below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Colchicine  

Approved for oral mucosal inflammatory disease in particular ‘Recurrent apthous stomatitis (RAS)’ and ‘Oral ulceration in Behcet’s disease’ (JFC April 2018).

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC, U&E and LFTs at 3 months, 6 months and then annually, CK only if myalgia.

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
09.06.04 Colecalciferol caps/liquid 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral liquid available as 3000 units/mL
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.04 Colecalciferol with Calcium carbonate Adcal-D3®

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.04 Colecalciferol with Calcium carbonate Calcichew-D3® Forte

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.12 Colesevelam Cholestagel®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.12 Colestipol Colestid®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.09.02 Colestyramine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.12 Colestyramine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.07 Colistimethate for nebulisation 

Secondary care notes

  • NMUH approvals:
    • Microbiology recommendation only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted Item Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Check with Microbiology
05.01.07 Colistimethate injection 

Secondary care notes

  • NMUH approvals:
    • Microbiology recommendation only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted Item Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Check with Microbiology
13.10.05 Collodion Flexible BP 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.01.01 Co-magaldrox 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Mucogel kept
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Suspension (Maalox) containing magnesium hydroxide 195mg, dried aluminium hydroxide 220mg/5ml. Na+ content 0.24mmol/5ml
09.02.02.01 Compound Sodium Lactate (Hartmann's) Intravenous Infusion 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • 500 mL and 1000 mL
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Conjugated oestrogen Premarin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • 300 microgram tablets are not kept at RFH
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Conjugated oestrogen with Medroxyprogesterone Premique®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Tabs containing conjugated oestrogens 625 micrograms and medroxyprogesterone acetate 5 mg ONLY
01.04.02 Co-Phenotrope 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.08 Co-trimoxazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to treatment and prevention of PCP infection; Chemotherapy protocols
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Oral suspension available as 40/200 mg/5mL and 80/400 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
A2.03.01 Cow and Gate Pepti-Junior 

Secondary care notes

  • NMUH approvals:
    • Suitable for infants from birth for:
      • protracted diarrhoea
      • food intolerance
      • short bowel
      • cystic fibrosis
      • inflammatory bowel disease
      • malnutrition
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Crisantaspase 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Crizotinib 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA drug safety alerts
    • See London Cancer Guidelines for the Treatment of Lung Cancer
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.03 Crotamiton 10% cream Eurax®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.02 Cyanocobalamin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Refer to blacklist exemptions under preparations
  • RNOH approval:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.06 Cyclizine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
    • Tablets approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
    • Injection approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Pre-op. emergency surgery: Reduce regurgitation/aspiration gastric contents
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
  • WH approvals:
    • Nil
11.05 Cyclopentolate eye drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Nil
11.05 Cyclopentolate eye drops - single use 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.01 Cyclophosphamide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.09 Cycloserine 

Secondary care notes

  • NMUH approvals:
    • Restricted for the use in combination with other drugs for Tuberculosis resistant to first line drugs only
  • RFL approvals:
    • Microbiology/ ID approval only
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted to TB clinic or as per Microbiology advice
03.04.01 Cyproheptadine 

Secondary care notes

  • NMUH approvals:
    • Stocked in the Emergency Drug Cupboard ONLY as an antidote for serotonin syndrome.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.03.04.02 Cyproterone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.02 Cyproterone Acetate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • In view of hepatotoxicity associated with long-term daily doses of 300 mg daily, the CSM recommend the use of cyproterone in prostatic cancer should be restricted to:
      • Short courses to cover testosterone flare associated with LHRH agonists.
      • Treatment of hot flushes after orchidectomy or LHRH agonists.
      • Patients who do not respond to, or are intolerant of other treatments.
    • Tabs 50 mg, 100 mg
08.01.03 Cytarabine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.03 Cytarabine liposomal DepoCyte®

Approved for the treatment of lyphomatous meningitis (intrathecal use only) (JFC April 2015)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.02 Dabigatran 

See NICE TA for eligibity criteria

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for thromboprophylaxis post elective total hip or knee replacement surgery and emergency hip fracture surgery, as per Trust guidelines.
    • See links below
    • Check MHRA Drug Safety Updates
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and faxed to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted for use as thromboprophylaxis after elective hip and knee surgery
08.01.05 Dabrafenib caps 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Dacarbazine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.03.02 Daclatasvir  

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.02.04 Daclizumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.02 Dactinomycin 

Not approved for Relapsed/refractory acute myeloid leukaemia (AML) (JFC October 2016)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.07 Dalbavancin infusion 

Approved if recommended by Microbiology for skin and soft tissue infections in patients only if (JFC April 2017):

  • unable to receive oral therapy and
  • available treatment pathways for repeated IV antibiotics are unsuitable e.g. chaotic lifestyle, immobility, poor venous access

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Skin and soft tissue infections in patients unable to receive oral therapy- Restricted to Microbiology recommendation (JFC April 2017)
  • WH approvals:
    • As above (restricted to Microbiology)
02.08.01 Danaparoid 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • See links below
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
06.07.02 Danazol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.02.02 Dantrolene sodium 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.08 Dantrolene sodium injection 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Dantrolene Injection is kept in the following locations: Main Theatres, Obstetrics Theatre
06.01.02.03 Dapagliflozin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL approvals:
    • Restricted to Endocrinology
  • RNOH approvals
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.10 Dapsone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Microbiology/ID approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Dapsone 

Approved for oral mucosal inflammatory conditions: mucous membrane pemphigoid (MMP), recurrent aphthous stomatitis (RAS) and linear IgA bullous dermatosis (JFC April 2018)

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC and reticulocyte count weekly for four weeks, monthly for 6 months, then every 3 months thereafter. LFTs should be monitored monthly for 3 months, then every 3 months thereafter for duration of therapy.

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
05.01.07 Daptomycin 

Store in a refridgerator

Secondary care notes

  • NMUH approvals:
    • Consultant Microbiologist approval only
  • RFL approvals:
    • Microbiology approval required
  • RNOH approvals
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
08.02.04 Daratumumab injection 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA
09.01.03 Darbepoetin alfa Aranesp®

Secondary care notes

  • NMUH approvals:
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
  • RFL approvals:
    • Restricted to renal team only
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA 323
05.03.01 Darunavir 

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL approvals:
    • Restricted to use as per London HIV consortium guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • For TB / HIV clinic only
05.03.01 Darunavir + Cobicistat Rezolsta®

Secondary care notes

  • NMUH approvals:
    • To be initiated by Consultants in HIV Medicine only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.01 Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide Symtuza®

Approved for HIV infection in line with NHSE commissioning policy F03/P/b (JFC January 2019)

 Secondary care notes

  • NMUH approvals:
    • To be prescribed by the HIV team only, as per the clinical commissioning policy - see link below.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.03.02 Dasabuvir 

Secondary care notes

  • NMUH approvals:
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Dasatinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.02 Daunorubicin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.02 Daunorubicin liposomal DaunoXome®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.03 Deferasirox 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Prior funding approval required
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.02 Deferasirox (free of charge)  

Deferasirox film-coated tablets (post-trial access) for transfusion related iron-overload in transfusion dependant thalassaemia and sickle cell disease (or non-transfusion dependant iron overload in patients with thalassaemia intermedia) (JFC November 2016)

09.01.03 Deferiprone 

Secondary care notes

  • NMUH approvals:
    •  To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Tabs 500 mg ONLY
06.03.02 Deflazacort 

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to Rheumatology and Endocrinology only.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Degarelix 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL approvals:
    • Restricted to urology and Dr Pigott.
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.09 Delamanid 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH approvals:
    • TB clinic only
05.01.03 Demeclocycline 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • ???
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • ???
  • WH approvals:
    • Microbiology approval only
06.05.02 Demeclocycline 

Secondary care notes

  • NMUH approvals:
    • For treatment of SIADH
  • RFL approvals:
    • ???
  • RNOH approvals
    • Treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Initially 0.9–1.2 g is given daily in divided doses, reduced to 600–900 mg daily for maintenance.
  • UCLH approvals:
  • WH approvals:
    • ???
06.06.02 Denosumab XGEVA®

Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by the Oncology team ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Giant cell tumour of bone
  • UCLH approvals:
  • WH approvals:
    • Nil
06.06.02 Denosumab Prolia®

Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Rheumatology and Care of the Elderly Consultants ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL approvals:
    • Approved for osteoporosis treatment by Endocrinology, Rheumatology
  • RNOH approvals:
    • Store in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Also approved for osteoporosis in men unable to take oral biphosphonates and unable to receive IV zoledronic acid due to renal dysfunction (November 2017)
20 Denosumab XGEVA®

Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018).

Only on the advice of oncology or palliative care consultants.

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
07.02.02 Dequalinium chloride vaginal tablets 

Approved for bacterial vaginosis as a second-line alternative to clindamycin 2% intravaginal cream in patients who have not tolerated or failed metronidazole treatment (JFC August 2018).

Secondary care notes

  • NMUH approvals:
    • Restricted to GU medicine ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
13.02.01 Dermamist® spray application 

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Restricted to Paediatric Dermatology outpatients.
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

13.02.02 Derma-S® barrier preparation 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
13.02.01 Dermatonics Once Heel Balm® Urea 25%

JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See indication above.
    • Restricted to podiatry use ONLY
13.02.01 Dermol® 500 lotion 

Secondary care notes

  • NMUH approvals:
    • Restricted to the Dermatology team
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.03 Desferrioxamine Mesilate 

Secondary care notes

  • NMUH approvals:
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL approvals:
    • Prior funding approval required for desferrioxamine infusors.
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
18 Desferrioxamine Mesilate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.02 Desflurane 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.01 Desloratadine 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • The use of desloratadine is reserved for consultant ENT surgeons only
    • Tabs 5mg ONLY
06.05.02 Desmopressin 

Secondary care notes

  • NMUH approvals:
    • DDAVP: On formulary
    • DesmoMelt: Formulary for use as a first line agent in the treatment of primary nocturnal enuresis
  • RFL approvals:
    • DDAVP: Restricted to child health; sublingual tablets not available at RFH
    • Desmotabs: Restricted to child health
    • Desmospray: On formulary
    • Octim: On formulary
  • RNOH approvals:
    • Tablets, Injection, Nasal spray (for continuation of treatment), Oral lyophilisates (for continuation of treatment)
  • UCLH approvals:
  • WH approvals:
    • DDAVP: Intranasal solution 100 micrograms/1 ml & Inj 4 micrograms/1 ml ONLY
    • DesmoMelt: The use of Desmomelt tablets is restricted to Paediatrics only
    • Desmotabs: The use of desmopressin tablets is restricted to Dr Rossi only
    • Desmospray: On Formulary
07.03.02.01 Desogestrel 75mcg pill generic, Cerazette®, Cerelle®, other brands available

Secondary care notes

  • NMUH approvals:
    • Preferred brand = generic
    • Restricted to Consultants in GU Medicine ONLY
  • RFL approvals:
    • Approved for Sexual Health and Family Planning (Marlborough Clinic). Also approved for Obs and Gyn.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.02.02 Dexamethasone 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil  
  • UCLH approvals:
  • WH approvals:
    • Nil
11.04.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.01.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.01.01 Dexamethasone + Neomycin + Glacial Acetic Acid ear spray  Otomize®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to ENT department use only
11.04.01 Dexamethasone + Neomycin + Polymyxin B drops, ointment Maxitrol®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.01.01 Dexamethasone 0.1% + Ciprofloxacin 0.3% ear drops Cilodex®

Approved for treatment of acute otitis externa with perforated/damaged tympanic membrane (JFC March 2018)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
11.04.01 Dexamethasone 0.1% eye drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.04.01 Dexamethasone 0.1% eye drops - preservative free 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Dexamethasone eye drops 0.1% preservative-free (Moorfields)
11.04.01 Dexamethasone intravitreal implant Ozurdex®

 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL approvals
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.03.02 Dexamethasone oral and systemic injection 

Secondary care notes

  • NMUH approvals:
    • See MHRA Drugs Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral solution available as 2 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • The use of dexamethasone inj 24mg/ml is restricted to theatres only
04.04 Dexamfetamine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable  
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As per NICE TA98 / CG87
08.01 Dexrazoxane Cardioxane®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.02.02.02 Dextran 70 + Sodium chloride hypertonic intravenous 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • RescueFlow bags are not kept at RFH.
    • The following are available at RFH (i) Dextran 70 6% and Sodium chloride 0.9% 500ml bags and (ii) Dextran 70 6% and Glucose 5% 500ml bags.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.02.02.02 Dextran 70 intravenous 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Dextran 70 6% and Sodium chloride 0.9% 500ml bags
    • Dextran 70 6% and Glucose 5% 500ml bags.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.02 Diamorphine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.01.02 Diazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Tablets 2 mg, 5 mg, 10 mg.
    • Oral solution 2 mg/5 ml, 5mg/5 ml 
    • Injection (emulsion) 10 mg/2 ml - Diazemuls
04.08.02 Diazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only diazepam injection (emulsion) and rectal solution stocked
  • RNOH approvals:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • ‘Diazemuls’ are preferred to plain diazepam injection as they are less likely to cause thrombophlebitis
10.02.02 Diazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.04.01 Diazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.04 Diazoxide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Dibotermin Alfa, rhBMP-2 Inductos®

 Secondary care notes

  • RNOH approvals:
    • Complex spinal funsion surgeries in line with NHSE commissioning policy
    • Restricted Item Restricted This product is currently unavailable in the UK
13.08.01 Diclofenac 3% gel Solaraze®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatologists
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
10.01.01 Diclofenac Sodium  

Secondary care notes

  • NMUH approvals:
    • See MHRA Drug Safety Update
  • RFL approvals:
    • Restricted to Rheumatology and Obstetricians / Gynaecology
  • RNOH approvals
    • Restricted: Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).
  • UCLH approvals:
  • WH approvals:
    • See MHRA Drug Safety Update
10.01.01 Diclofenac sodium + Misoprostol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Must not be given to women of child-bearing potential
11.08.02 Diclofenac Sodium 0.1% eye drops - single use Voltarol® Ophtha

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to Opthalmology
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Diclofenac sodium Modified release 

Secondary care notes

  • NMUH approvals:
    • Not applicable
    • Check MHRA Drug Safety Updates 
  • RFL approvals:
    • Restricted to only Rheumatology and Obs / Gynae
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See MHRA Drug Safety Update
18 Dicobalt edetate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.02 Dicycloverine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.01 Didanosine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.03.01 Diethylstilbestrol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Diflucortolone valerat 0.3% - Topical Nerisone Forte®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Oily Cream ONLY
13.04 Diflucortolone valerate 0.1% - Topical Nerisone®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Oily cream and Ointment are available at the Royal Free Hospital
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.01.01 Digoxin 

Secondary care notes

  • NMUH approvals:
    • NB. The Digoxin 100 micrograms/mL (Paediatric) is unlicensed and NON-FORMULARY. 
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Tablets available. Oral elixir available as 50 micrograms/mL
  • UCLH approvals:
  • WH approvals:
    • Nil
02.01.01 Digoxin specific antibody fragments Digifab®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Dihydrocodeine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Oral elixir available as 10 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Dihydrocodeine modified release  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.04.02 Diloxanide 

Secondary care notes

  • NMUH approvals:
    • Not applicable  
  • RFL approvals:
    • Microbiology/ID approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
21.01 Diltiazem cream 

Diltiazem cream for transrectal ultrasound guided prostate biopsy
Twelve-month evaluation at UCLH site only (March 2015)

01.07.04 Diltiazem Cream 2% 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.06.02 Diltiazem immediate release 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.06.02 Diltiazem modified release 

Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable.

Secondary care notes

  • NMUH approvals:
    • Adizem-SR, Adizem-XL, Tildiem LA, Tildiem Retard available
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Tildiem LA, Tildiem Retard available
08.02.04 Dimethyl fumarate Tecfidera®

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drugs Safety Updates
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.01.01 Dinoprostone Prostin E2®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Intravenous solution and Vaginal Gel are kept at the Royal Free Hospital
    • See link below
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Vaginal gel 1 mg/2.5 ml (Prostin E2), Vaginal gel 2 mg/2.5 ml (Prostin E2) Inj 5 mg/0.5 ml extra amniotic
07.01.01 Dinoprostone Propess®

Secondary care notes

  • NMUH approvals:
    • Restricted to Obstetrics and Gynaecology Consultants only for induction and Augmentation of Labour
  • RFL approvals:
    • See link below
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Diphtheria antitoxin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Unlicensed product
13.02.01 Diprobase® cream 

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology team
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • 50g, 500g only
02.09 Dipyridamole 

See NICE TA for eligibility

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01 Disodium Folinate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.03.02 Disopyramide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.10.01 Disulfiram 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.02 Dithranol cream Dithrocream®

Secondary care notes

  • NMUH approvals:
    • Dithrocream 0.25% and Dithrocream 0.5% are FORMULARY, for irritation on trunk and limbs.
    • Dithrocream 0.1%, Dithrocream 1% and Dithrocream 2% are NON-FORMULARY.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.05.02 Dithranol Paste, BP 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.07.01 Dobutamine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Docetaxel 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL approvals:
    • Restricted for treatment of breast, prostate and non-small cell lung cancers
    • Prior funding approval required for treatment of prostate cancer and adjuvant treatment of breast cancer
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Breast and lung cancer
08.01.05 Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT) 

Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • As above
  • WH approvals:
    • Not applicable
12.01.03 Docusate 0.5% eardrops Waxsol®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Available at the RNTNE only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.06.02 Docusate sodium 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approval:
    • Caps 100mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
  • UCLH approvals:
  • WH approvals:
    • Caps 100 mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
05.03.01 Dolutegravir 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.01 Dolutegravir + Abacavir + Lamivudine Triumeq®

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.02 Domperidone 

Secondary care notes

  • RNOH approvals: 
    • Tablets availabe. Oral suspension available as 1 mg/mL
  • WH approvals:
    • See MHRA safety alert
  • RFL approvals: 
    • See MHRA safety alert
04.06 Domperidone 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Drug Updates
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Oral suspension available as 1 mg/mL 
  • UCLH approvals:
  • WH approvals:
    • Risk of cardiac side effects - to be used at the lowest effective dose for the shortest period of time
04.11 Donepezil 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Care of the Elderly consultants only
    • Tabs 5mg only
02.07.01 Dopamine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.07.01 Dopexamine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only available for liver transplant patients and continuation of treatment.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.06 Dorzolamide 2% + Timolol 0.5% eye drops Cosopt®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Dorzolamide 2% + Timolol 0.5% eye drops - unit dose Cosopt®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Restricted to Ophthalmology 
11.06 Dorzolamide 2% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not to be used as first-line treatment - see link below
11.06 Dorzolamide 2% eye drops - unit dose 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.03.01 Dosulepin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.04.02 Dosulepin 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.02.01 Doublebase® gel 

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.05.01 Doxapram 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.04 Doxazosin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Immediate release preparations only.
    • Prolonged release preparations not recommended for routine use by NHSE (Dec 2017)
07.04.01 Doxazosin 

Secondary care notes

  • NMUH approvals:
    • Modified release praparations are non-formulary
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Modified release praparations are non-formulary
08.01.02 Doxorubicin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Inj 50 mg ONLY
08.01.02 Doxorubicin pegylated liposomal Caelyx®

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.03 Doxycycline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.04.01 Doxycycline 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.03.02 Dronedarone 

Secondary care notes

  • NMUH approvals:
    • NOT 1ST LINE DRUG - REQUIRES CARDIOLOGIST APPROVAL.
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Requires CARDIOLOGIST approval
  • UCLH approvals:
  • WH approvals:
    • For use in the treatment of Non‐Permanent Atrial Fibrillation (AF) where it is not the first‐line option; this is use is limited to an SpR or a Consultant cardiologist who has seen the patient.
06.01.02.03 Dulaglutide 

Liraglutide and dulaglutide are  the preferred GLP-1RAs for type 2 diabetes, when used in line with the NCL Fact sheet (JFC July 2018)

Secondary care notes

  • NMUH approvals:
    • Non-formulary but see link below
  • RFL approvals:
    • Restricted to Endocrinology only
  • RNOH approvals
    • Requires initiation by a Diabetes Specialist
  • UCLH approvals:
  • WH approvals:
    • As above
04.03.04 Duloxetine Cymbalta®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.03 Duloxetine Cymbalta®

Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin. Refer to the NCL JFC Neuropathic Pain Prescribing Guideline below.

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin.
    • See link below
  • UCLH approvals:
  • WH approvals:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin
    • See link below
07.04.02 Duloxetine Yentreve®

DO NOT CONFUSE CYMBALATA® AND YENTREVE® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Secondary care notes

  • NMUH approvals:
    • Duloxetine (Yentreve) is FORMULARY for use in women with moderate to severe urinary stress incontinence. Duloxetine (Yentreve) should be used as a second line option for urinary stress incontinence, as an alternative to surgical treatment, as per NICE guidance.
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
A5.02.04 DuoDERM Extra Thin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.01.02 Durafiber 

Absorbent Cellulose dressing with gel matrix 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A5.03.03 Durafiber Ag 

Secondary care notes

  • NMUH approvals:
    • To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Dutasteride 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved for use by Dermatology for frontal fibrosing alopecia (third line drug. Off label use)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 E45® cream 

Secondary care notes

  • NMUH approvals:
    • E45 cream is NON-FORMULARY.
    • Cetomacrogel A cream (500g) is used at NMUHT.
  • RFL approvals:
    •  Not applicable
  • RNOH approvals
    •  Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

A5.02.03 Eclypse Adherent 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.02.02 Econazole Gyno-Pevaryl®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Gyno-Pevaryl 'Single dose' Pessary kept at RFH
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.03.02 Econazole 1% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • This is an unlicensed special and restricted to Ophthalmology
09.01.03 Eculizumab 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • See links below
  • WH approvals:
    • Not applicable
21.02 Eculizumab (free of charge)  

Approved for Cold Agglutinin Disease (July 2016, October 2016)

Secondary care notes

  • RFL approvals:
    • Nil
  • UCLH approvals:
    • Waldenstrom's macroglobulinaemia. For CAD under Dr D'Sa's clinic as last line option - UMC June 2016
02.08.02 Edoxaban 

See NICE TA for eligibity criteria

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA - This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not to be used for initiation of therapy.
05.03.01 Efavirenz 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
13.09 Eflornithine 11.5% cream Vaniqa®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to dermatology and endocrinology only
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
05.03.03.02 Elbasvir + Grazoprevir 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A2.01.01.02 Elemental 028 ® Extra 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.08.01 Eliglustat 

Approved for type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers (JFC November 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Gaucher disease in line with NICE HST
  • WH approvals:
    • Not applicable
09.01.04 Eltrombopag 

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines see link below.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See links below
01.04.02 Eluxadoline 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • NICE TA471 applies
06.01.02.03 Empagliflozin 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL approvals:
    • Restricted to Endocrinology
  • RNOH approvals
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Emtricitabine 

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
    • Patients currently benefiting from FTC in their combination therapy, who either accessed FTC in studies or move to London with FTC as part of their existing regimen, should continue to receive FTC without interruption
    • For patients who have previously not received 3TC, the decision to prescribe 3TC or FTC to be made by the clinician and patient after discussion and consideration of relevant factors
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For TB / HIV clinic only
05.03.01 Emtricitabine + Rilpivirine + Tenofovir disoproxil Eviplera®

Secondary care notes

  • NMUH approvals:
    • NHSE approval required
    • Initiation restricted to Consultants HIV Medicine
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.01 Emtricitabine + Tenofovir alafenamide Descovy®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01.01 Emulsiderm® liquid emulsion 

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology team
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 Emulsifying Ointment, BP 

Secondary care notes

  • NMUH approvals:
    • Stock 500g tub
    • Emulsifying ointment can be used as a soap substitute
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.05.01 Enalapril  

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Enfuvirtide 

Secondary care notes

  • NMUH approvals:
    • To be used in accordance with the London HIV consortium BHIVA guidelines
    • For HIV team only
    • Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
  • RFL approvals:
    • Restricted to use as per London HIV consortium guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.01 Enoxaparin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • For the treatment of acute coronary syndrome only Low molecular weight heparin protocol
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.01.02 Enoximone 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.04.01.02 Enshake 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.03 Ensure Compact 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.01 Ensure Plus Advance 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.01 Ensure Plus Fibre 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.01.02 Ensure Plus Juce 

Secondary care notes

  • NMUH approvals:
    • Taste aberrations/aversions to milky supplements, fat intolerance/streatorrhoea, Cancer cachexia, poor wound healing, anorexia, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished. Proven inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagia Non-milk tasting. For patients who dislike milk. Used to meet nutritional requirements in addition to oral intake
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.01 Ensure Plus Milkshake style 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.01 Ensure Plus Yoghurt style 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.01.02.03 Ensure Twocal 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.09.01 Entacapone 

Secondary care notes

  • NMUH approvals:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see link)
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Entacapone is available for use by Care of the Elderly and Neurology Consultants only
05.03.03.01 Entecavir 

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.03.04.02 Enzalutamide 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable to WH
13.02.01 Epaderm® cream/ointment 

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

 

02.07.02 Ephedrine 

Secondary care notes

  • NMUH approvals:
    • Restricted for use in Theatres only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • In idiopathic orthostatic hypotension in spinally injured patients
  • UCLH approvals:
  • WH approvals:
    • Ephedrine inj is available for use by anaesthetists only.
12.02.02 Ephedrine 0.5% nasal drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.01.01.02 Ephedrine tablets 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Ephedrine tablets 

Secondary care notes

  • NMUH approvals:
    • Approved for use for priaspism (unlicensed use).
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.02 Epirubicin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.02.03 Eplerenone 

Approved for heart failure in patients unable to tolerate spironolactone due to gynacomastia (JFC April 2017)

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
    • Restricted for patients who are unable to tolerate spironolactone due to gynaecomastia
  • RFL approvals:
    • Restricted to Cardiology
  • RNOH approvals:
    • Requires CARDIOLOGIST approval
  • UCLH approvals:
    • Restricted to patients intolerant of spironolactone due to gynacomastia
  • WH approvals:
    • Eplerenone is reserved for the use of Consultant Cardiologists only for those who develop gynaecomastia with spironolactone
09.01.03 Epoetin alfa Eprex®

Secondary care notes

  • NMUH approvals:
    • For anaemia associated with chronic renal failure only.
    • Restricted to renal consultants signature and Dr. Tindall signature only.
    • Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Epoetin is available for treatment anaemia of renal disease only
09.01.03 Epoetin beta NeoRecormon®

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Renal and Haematology Consultants.
    • See MHRA drug safety updates 
  • RFL approvals:
    • Renal anaemia
  • RNOH approval
    • Store in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Epoetin is available for treatment anaemia of renal disease only
    • Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY
02.08.01 Epoprostenol 

Approved for pulmonary hypertension (November 2013)

Secondary care notes

  • NMUH approvals
    • Restricted for ICU use only.
    • Check MHRA for Drug Safety Updates
  • RFL approvals:
    • Restricted to ITU and pulmonary hypertension
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Approved for primary pulmonary hypertension: functional grades III + IV
    • Approved for Inhibition of platelet aggregation during renal dialysis
  • WH approvals:
    • Nil
02.09 Eptifibatide Integrilin®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.04 Ergocalciferol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Inj 7.5 mg (300,000 units)/1 ml only
07.01.01 Ergometrine Maleate 

Secondary care notes

  • NMUH approvals:
    • Restricted to Obstetrics Only 
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.01.01 Ergometrine Maleate + Oxytocin Syntometrine®

Secondary care notes

  • NMUH approvals:
    • Restricted to Obstetrics ONLY
  • RFL approvals:
    • See Maternity Unit Guideline on Massive Obstetric Haemorrhage
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.04.01 Ergotamine Tartrate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Eribulin 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Prior funding approval required via CDF
    • Only available on Cancer Drugs Fund
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Erlotinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology team ONLY.
    • See links below
  • RFL approvals:
    • AS per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.02.02 Ertapenem 

Secondary care notes

  • NMUH approvals:
    • Microbiology approval only
  • RFL approvals:
    • Microbiology approval only
  • RNOH approvals
    • Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Restricted antibiotic - Microbiology approval only
01.02 Erythromycin 

Secondary care notes

  • RNOH approvals: 
    • Off-label use
  • WH approvals:
    • Off-label use
  • RFL approvals: 
    • Off-label use
05.01.05 Erythromycin 

Secondary care notes

  • NMUH approvals:
    • Injection is reserved for the use of Paediatrics only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Restricted to Maternity use or as prokinetic
11.03.01 Erythromycin 0.5% eye ointment 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • This is unlicensed special and restricted to Ophthalmology
13.06.01 Erythromycin 40mg + Zinc acetate 12mg/mL topical solution Zineryt®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.04 Esmolol 

Secondary care notes

  • NMUH approvals:
    • Only 100mg/10ml vials are kept at NMUHT.
  • RFL approvals:
    • Restricted to ITU, cardiology and theatre 8 only.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol Zumenon®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol Elleste-Solo®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.02.01 Estradiol 10mcg vaginal tablet Vagifem®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.02.01 Estradiol 7.5mcg /24hrs 7.5 microgram/24 hours vaginal delivery system Estring®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol gel Oestrogel®

Approved as hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women (JFC September 2018).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to the menopause clinic only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
06.04.01.01 Estradiol patch FemSeven®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol patch Evorel®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Transdermal patch 50 micrograms/24 hours,100 micrograms/24 hours ONLY. For patients requiring 25 micrograms of estradiol per day, the Evorel 50 micrograms patch may be cut in half.
06.04.01.01 Estradiol with Dydrogesterone Femoston

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Femoston-conti tablets & Femoston 1/10 tablets ONLY
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Conti

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Sequi

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Medroxyprogesterone Tridestra®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to gynaecology
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Norethisterone Climesse®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol with Norethisterone Elleste-Duet Conti®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • ???Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Norethisterone Elleste-Duet®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • ???Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Norethisterone Kliofem®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.04.01.01 Estradiol with Norethisterone Kliovance®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol with Norethisterone patch Evorel® Sequi

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Estradiol with Norethisterone patch Evorel® Conti

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.02.01 Estriol 0.01% vaginal cream Gynest®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.02.01 Estriol 1mg/1g vaginal cream Ovestin®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Etanercept 

JFC approved Benepali as the brand of choice.

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs below)
  • Ankylosing spondylitis (see NICE TAs below)
  • Psoriatic Arthritis (PsA; see NICE TAs below)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update
    • See links below
  • RFL approvals:
    • Prior funding approval required
    • Restricted to Rheumatology Consultants
    • See links below
  • RNOH approvals:
    • Rheumatology Consultants ONLY
    • Please prescribe by brand name Benepali or Enbrel - patients requiring 50 mg should be prescribed Benepali and patients requiring 25 mg should be prescribed Enbrel
    • See links below
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
13.05.03 Etanercept 

JFC approved Benepali as the brand of choice.

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists
    • Check MHRA safety updates.
    • See links below.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Etanercept 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Prior funding required
    • Restricted to National Amyloidosis Centre
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
05.01.09 Ethambutol  

Secondary care notes

  • NMUH approvals:
    • Nil (suspension 400mg/5ml [unlicensed] is available for the treatment of tuberculosis in children)
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.01.01 Ethinylestradiol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.03.01 Ethinylestradiol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.01 Ethinylestradiol / levonorgestrel phased pill 21-days TriRegol®, Logynon®

Secondary care notes

  • NMUH approvals:
    • Preferred brand = Logynon
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.01 Ethinylestradiol / levonorgestrel phased pill 28-days Logynon ED®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg pill 21-days Loestrin 20®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg pill 21-days Gedarel® 20/150, Mercilon®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 20/150
    • Preferred brand for Obs & Gynae = Mercilon
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Preferred brand = Mercilon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg pill 21-days Millinette® 20/75, Femodette®, Juliperla®, Sunya 20/75®

Secondary care notes

  • NMUH approvals:
    • Preferred brand = Millinette 20/75
    • Millinette 20/75 is restricted to Consultants in GU Medicine ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.01 Ethinylestradiol 30 mcg / norethisterone 1.5mg 21-days Loestrin 30®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg pill 21-days Gedarel® 30/150, Marvelon®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 30/150
    • Preferred brand for Obs & Gynae = Marvelon
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Preferred brand = Marvelon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg pill 21-days Millinette® 30/75, Femodene®, Sofiperla®, Katya 30/75®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY = Millinette 30/75
    • Preferred brand for Obs & Gynae = Femodene
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Preferred brands = Femodene
    • Millinette 30/75= for Community Clinics ONLY
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 21-days Rigevidon®, Microgynon 30®, Levest®, Ovranette®

Secondary care notes

  • NMUH approvals:
    • Restricted to GU Medicine ONLY = Rigevidon
    • For Obs & Gynae = Microgynon 30
  • RFL approvals:
    • Preferred brand = Microgynon 30
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Preferred brand = Microgynon 30
    • Rigevidon= Formulary item for Community Trust
07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg 21-days Norimin®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg pill 21-day Cilique®, Cilest®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • There is insufficient information to know if there is an increased risk associated with norgestimate.
04.08.01 Ethosuximide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Etilefrine 

Secondary care notes

  • NMUH approvals:
    • For treatment of priapism in patients with sickle cell disease
    • Etilefrine 25mg Tablets, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.01 Etodolac 

Secondary care notes

  • NMUH approvals:
    • Restricted to use by Rheumatology Consultants only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology only
10.01.01 Etodolac Modified Release  

Secondary care notes

  • NMUH approvals:
    • Restricted to use by Rheumatology Consultants only
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology only
15.01.01 Etomidate Etomidate-Lipuro®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.01 Etomidate Hypnomidate®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.02.02 Etonogestrel 68mg subdermal implant Nexplanon®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY.
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.04 Etoposide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Etravirine 

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Everolimus Votubia®

Approved for renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (July 2013)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • See indication above
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable

QUERY RFL

08.01.05 Everolimus Afinitor®

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • TA432, 449 and 498 do not apply at NMUH as services not offered.
    • See links below
  • RFL approvals:
    • Prior funding approval required via CDF for RCC and Breast Ca
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.02 Everolimus (compassionate access) Afinitor®

Approved for pancreatic NET (as part of compassionate access program) at RFL only.

02.12 Evolocumab 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.01 Exemestane 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Exemestane is indicated for 3rd line treatment (after tamoxifen and anastrazole) in post-menopausal women with metastatic breast cancer
02.12 Ezetimibe 

Primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high intensity statins have failed to sufficiently reduce cholesterol levels

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Restricted to lipid clinic
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of ezetimibe is reserved as a 3rd line agent where treatment with simvastatin, and then atorvastatin has failed, and for patients for whom the use of a statin is contraindicated, or who are statin intolerant, in accordance with the NICE guidance.
02.11 Factor VIIa (Recombinant) Novo 7®
02.11 Factor VIII Fraction, Dried 
05.03.02.01 Famciclovir 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Microbiology use only
10.01.04 Febuxostat 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists or under the direction of a Consultant Rheumatologist.
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • See link below
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA
10.03.02 Felbinac 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to the Rheumatology team ONLY
    • Available over the counter without a prescription
02.06.02 Felodipine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.12 Fenofibrate 

Secondary care notes

  • NMUH approvals:
    • Lipantil stocked
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 160mg tablets only
15.01.04.03 Fentanyl 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Controlled Drug Requirements
  • RNOH approvals
    • Restricted Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Fentanyl buccal tablets Effentora®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone.
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.07.02 Fentanyl patch 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
21.01 Fentanyl patch 

Fentanyl patch for acute post-operative pain in primary knee replacement surgery
30 patient evaluation at RNOH site only. Evaluation to be reviewed at JFC (April 2015)

04.07.02 Fentanyl sublingual tablets Abstral®

Approved for the treatment of breakthrough, chronic, cancer pain in palliative patients taking opioid agonists, who are unable to obtain relief from, or are intolerant to, oral morphine and oxycodone immediate release. Pain or Palliative Care recommendation only (JFC September 2018).

Secondary care notes

  • NMUH approvals:
    • Restricted to haematology and palliative care teams only
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
09.01.01.02 Ferric Carboxymaltose Ferinject®

See local guidance for iron replacement

Approved for:

  1. Iron deficient anaemia in Obstetrics (January 2017)
  2. Iron deficient anaemia in adult outpatients only, not in patients in first trimester of pregnancy or for patient on haemodialysis (March 2017)

 

Secondary care notes

  • NMUH approvals:
    • To be used for day case patients and out patients ONLY
    • See link below for parenteral irons prescribing guideline.
    • Ferinject must be prescribed on the specific Daycase Ferinject prescription form; see link below
    • Note: Parenteral iron is contraindicated in the first trimester of pregnancy. For dose of Ferinject in patients with haemodialysis dependent chronic kidney disease, refer to the summary of prouct characteristics.
    • Check MHRA Drug Safety updates
  • RNOH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Renal units and gastroenterology only
  • UCLH approvals:
    • Restricted to outpatients / daycase / facilitate inpatient discharge
  • WH approvals:
    • Parenteral iron should only be considered if oral therapy has failed due to lack of patient co-operation, severe gastrointestinal side effects, continuing severe blood loss or malabsorption. Provided oral therapy is taken reliably and is absorbed, then the haemoglobin response is not significantly faster with the parenteral route.
17 Ferric subsulphate solution  Monsels

Approved as a haemostatic agent in colposcopy (JFC January 2019)

Secondary care notes

  • NMUH approvals:
    • As above
  • RFL approvals:
    •  Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As above
09.01.01.01 Ferrous fumarate 

Secondary care notes

  • NMUH approvals:
    • Nil (not Galfer)
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Oral syrup available as 140 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Oral syrup available as 140 mg/5mL (ONLY formulation available)
09.01.01.01 Ferrous fumarate + Folic acid Pregaday®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.01.01.01 Ferrous gluconate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Ferrous gluconate contains a lower content of elemental iron and therefore may be better tolerated than ferrous sulphate.
09.01.01.01 Ferrous sulphate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • First choice for iron-deficiency anaemia
  • UCLH approvals:
  • WH approvals:
    • Nil
09.01.01.01 Ferrous sulphate modified release Ferrograd®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.04.01 Fexofenadine 

Additionally approved for the treatment of chronic spontaneous urticaria at a 'high dose' for patients who do not respond to 'high dose' cetirizine (JFC November 2018).  Notes: initiate at 180mg daily and increase according to response to a maximum of 360mg twice-daily (720mg daily).

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Restricted to dermatology only.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • As above
17.01 Fibrin Sealant Evicel®

Approved for Dura matter closure (July 2015)


Secondary care notes

  • RNOH approvals
    • Restricted for soft tissue sarcoma surgery, primary bone tumour surgery, complex revision hip and knee surgery and dura mater closure
17.01 Fibrin Sealant Tisseel® Ready to Use

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
  • MEH approvals:
    • Approved for conjunctival surgery in preference to sutures for pterygium surgery (January 2013)
21.01 Fibrin sealant Artiss®

Simple mastectomies - as part of the '23 hour mastectomy' pathway
Under evaluation at RFL only (October 2017)

05.01.07 Fidaxomicin 

Consultant microbiologist approval only for multiple recurrent Clostridium difficile infections (at least three). Fidaxomicin could also be used in patients in extremis when all other drugs had failed (October 2012)

Secondary care notes

  • NMUH approvals:
    • Microbiology approval only
  • RFL approvals:
    • Not applicable  
  • RNOH approvals
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
09.01.06 Filgrastim Neupogen®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to hepatology out-patients only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.06 Filgrastim Zarzio®

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drugs Safety Alerts
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Requires HAEMATOLOGIST approval
    • Store in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Nil
06.04.02 Finasteride 

Secondary care notes

  • NMUH approvals:
    • Restricted to Urology use only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Finasteride should be initiated by urology only for the treatment of patients with BPH in whom alpha-blockers have failed.
08.02.04 Fingolimod 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.04.02 Flavoxate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.03.02 Flecainide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.03 Flecainide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Specialist use only
21.01 Florbetapir F 18 injection 

Amyvid (florbetapir) for Alzheimer's disease
10 patient evaluation at RFL site only. Evaluation to be reviewed at JFC (JFC September 2014 and February 2015)

17.01 Flowable haemostatic agent with thrombin Surgiflo®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

17.01 Flowable haemostatic agent with thrombin Floseal®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

13.04 Flucinolone Acetonide 0.0025% - Topical Synalar 1 in 10 Dilution®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.01.02 Flucloxacillin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.02 Fluconazole 

Secondary care notes

  • NMUH approvals:
    • Infusion restricted to Microbiology Consultants use only
  • RFL approvals:
    • Intravenous preparations restricted to Haematology; Oncology; HIV; Renal unit; Liver unit. Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted antifungal. Microbiology approval only
05.02 Flucytosine 

Secondary care notes

  • NMUH approvals:
    • Restricted to Microbiology Consultants use only
  • RFL approvals:
    • Restricted to HIV; Haematology; Oncology; Transplant patients
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
20 Flucytosine tablets 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 500mg tablets
08.01.03 Fludarabine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.03.01 Fludrocortisone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Fludroxycortide - topical Haelan®

Secondary care notes

  • NMUH approvals:
    • Haelan tape is FORMULARY, for use on keloid scars only.
    • Haelan cream and Haelan ointment are NON-FORMULARY.
  • RFL approvals:
    • Restricted to Dermatologists only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Tape only
15.01.07 Flumazenil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • NPSA guidance on conscious sedation policy.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Flumazenil is used to reverse the sedative effects of benzodiazepines in anaesthetic, intensive care and diagnostic procedures. It should not be used for routine benzodiazepine reversal. It has a shorter half-life than diazepam and midazolam and care is required to avoid the risk of resedation.
12.01.01 Flumetasone 0.02% + Clioquinol 1% ear drops Locorten-Vioform®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Fluocinolone acetonide 0.00625% - Topical Synalar 1 in 4 Dilution®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Cream available at the Royal Free Hospital.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Fluocinolone acetonide 0.025% - Topical Synalar®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Gel 0.025% (Synalar) 30g ONLY
13.04 Fluocinolone acetonide 0.025% + Clioquinol 3%- Topical Synalar C®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.04.01 Fluocinolone acetonide intravitreal implant Iluvien®

 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL approvals
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Diabetic macular oedema after an inadequate response to prior therapy (Nov 2013 TA301)
13.04 Fluocinonide 0.05% - Topical Metosyn®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 FluorEscein 20% injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
11.08.02 Fluorescein eye drops - unit dose 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • 1% fluorescein sodium is not kept at RFH
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 2% only
11.08.02 Fluorescein paper strips 1mg 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.03 Fluorides En-De-Kay® Tablet

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Islington Community Only - direct ward delivery
17 Fluorocholine-18F 

Secondary care notes

  • RFL approvals
    • PETC/CT imaging for staging of prostate cancer (RFL only, September 2013)
11.04.01 Fluorometholone 0.1% eye drops FML®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.03 Fluorouracil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.08.01 Fluorouracil 5% cream Efudix®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.03.03 Fluoxetine 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Caps 20mg. Liquid 20mg/5ml. Only
04.02.01 Flupentixol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Nil  
  • UCLH approvals:
  • WH approvals:
    • Depot injection only
04.03.04 Flupentixol 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Initiate after discussion with liaison psychiatry team.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.02.02 Flupentixol decanoate depot injection Depixol® Conc.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol® Low Volume

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Fluphenazine decanoate depot injection Modecate®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Fluphenazine decanoate depot injection Modecate Concentrate®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
10.01.01 Flurbiprofen 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.03 Flurides En-De-Kay® Oral Drops

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Islington community only
09.05.03 Flurides Duraphat® Toothpaste

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 0.619% toothpaste available for Simmons House and Islington community clinics only 
08.03.04.02 Flutamide 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Oncologist and Urologist use only
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
03.02 Fluticasone + Formoterol inhaler Flutiform®

Approved for asthma requiring a combined ICS/LABA (May 2013)

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.02 Fluticasone + Salmeterol inhaler Sirdupla®, Seretide®

Secondary care notes

  • NMUH approvals:
    • See links below
    • Seretide 125 & 250 Evohalers and are NON-FORMULARY, except in paediatric patients.
    • Seretide 500 is non-formulary. AirFlusal Fospiro 50/500 should be used instead. See link below for further information.
  • RFL approvals:
    • Nil
  • RNOH approval
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Approved for prescribing by Respiratory Team only. All pharmacists must ensure inpatients have been reviewed by Respiratory Nurse Specialist before supplying prior to prescribing.
03.02 Fluticasone furoate + Vilanterol inhaler Relvar Ellipta®

Approved for:

  • COPD (JFC February 2017)
  • Asthma (JFC May 2017)
  • Adolescent asthma; age 12-19 (JFC May 2019)

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
12.02.01 Fluticasone furoate 27.5mcg/spray nasal spray 

Secondary care notes

  • NMUH approvals:
    • Restricted for use in paediatric patients ONLY
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.02 Fluticasone inhaler Flixotide®

Secondary care notes

  • NMUH approvals:
    • Restricted to Paediatric Consultants use only.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted
  • UCLH approvals:
  • WH approvals:
    • Turbohalers, Accu-halers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • 50 micrograms, 125 micrograms, 250 micrograms/metered inhalation CFC-Free (Flixotide Evohaler) & Accu- haler 500 micrograms/ metered inhalation ONLY
20 Fluticasone inhaler 

Approved as first-line choice (before budesonide nasules) for eosinophilic oesophagitis in adults. Fluticasone Accuhaler (dry powder inhaler) '250' should be sucked 1-2 doses twice daily and down titrate dose for maintenance dosing (JFC February 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • As above
13.04 Fluticasone propionate - Topical Cutivate®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to paediatrics only.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.02 Fluticasone propionate + Salmeterol AirFluSal Forspiro®

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • Not applicable
12.02.01 Fluticasone propionate 400mcg/unit nasal drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.02.01 Fluticasone propionate 50mcg/spray nasal spray 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Fluticasone propionate nasules / nasal spray 

Approved for Oral lichen planus after failure of betamethasone (JFC June 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • Indicated for oral linchen planus (OLP) only
02.12 Fluvastatin 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Restricted to liver and renal patients only.
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
04.03.03 Fluvoxamine Maleate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.02 Folic Acid 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Folic acid is indicated in confirmed folate deficiency due to dietary lack, gastrointestinal disease, pregnancy, chronic haemolytic states, myeloproliferative disorders, haemodialysis, and parenteral nutrition, intensive care of the very sick patient or in premature infants. Folic acid can be used to correct serious haematological changes caused by dihydrofolate reductase inhibitors (DFRIs), after the DFRI has been discontinued. Examples of DFRIs include trimethoprim and co-trimoxazole.
    • Before treating megaloblastic anaemia with folic acid alone, vitamin B12 deficiency MUST be excluded. Folic acid may relieve the haematological features of vitamin B12 deficiency and allow neuropathy to develop undetected. If treatment must be started immediately, both folic acid and hydroxocobalamin should be given.
08.01.05 Folinic acid + fluorouracil + irinotecan (FOLFIRI) 

Approved for:

  • 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
  • 2nd line for high grade neuroendocrine tumour (March 2016)
08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) 

Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015)

08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX) 

Approved adjuvant treatment of pancreatic cancer (JFC September 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
06.05.01 Follitropin Beta Puregon®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only 100 unit and 150 unit vials kept at RFH
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.01 Fondaparinux 

Secondary care notes

  • NMUH approvals:
    • Restricted to use for patients with Unstable Angina / NSTEMI.
    • See Trust Guideline on use
  • RFL approvals:
    • Restricted - only to be used under the advice of the haemophilia consultant
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted for use in unstable angina and NSTMEI
03.01.01.01 Formoterol fumarate Oxis® Turbohaler

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Turbohalers, Accuhalers and Autohalers are reserved for patients unable to tolerate an MDI with spacing device.
A2.02.02.03 Forticreme Complete 

Secondary care notes

  • NMUH approvals:
    • Stroke, Dysphagia, fluid restrictions, CAPD, HD, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished, inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagiaSemi-solid. High in protein. For dysphagia or requiring a soft diet, tolerating low volume of food
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.02.02.03 Fortisip Compact Protein 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.01 Fosamprenavir 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Foscarnet sodium 2% cream 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
05.03.02.02 Foscarnet sodium IV 

Secondary care notes

  • NMUH approvals:
    • Restricted for HIV patients use only.
  • RFL approvals:
    • Restricted to HIV; Transplant patients; Haematology; Oncology
    • Virology approval required for all other indications
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.07 Fosfomycin intravenous 

Microbiology approval only for treatment of infections, or suspected infections, caused by multi-drug resistant Gram-negative organisms, including ESBLs (JFC August 2016)

Secondary care notes

  • NMUH approvals:
    • Should only be prescribed following advice from a Consultant Microbiologist
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
05.01.07 Fosfomycin oral sachets 

Approved for prescribing in primary and secondary care for symptomatic UTI sensitive to fosfomycin, where patients are unable to receive, or the organism is resistant to, first-line antibiotics (July 2015)

Secondary care notes

  • NMUH approvals:
    • Consultant Microbiology approval only
  • RFL approvals:
    • As a last line-salvage therapy for deep seated bone, vascular and organ space infections only on approval of an Infectious Diseases or Microbiology consultant
  • RNOH approvals:
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
08.03.04.01 Fulvestrant 

Secondary care notes

  • NMUH approvals:
    • To be prescribed by Oncology Consultants ONLY
    • See indication above
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See indication above
02.02.02 Furosemide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.03.01 Fusidic Acid 1% gel 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Paediatrics and Ophthalmology out-patients
04.07.03 Gabapentin 

Second choice agent for neuropathic pain. Refer to the NCL JFC Neuropathic Pain Prescribing Guideline below.

 Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • See link below
  • UCLH approvals:
  • WH approvals:
    • As per JFC guideline; also for orthopaedics - post surgery
04.08.01 Gabapentin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Should only be commenced on the recommendation of a Neurologist
    • Neurontin available as 100mg and 300mg capsules
04.11 Galantamine 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.11 Galantamine modified release 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.03.03 Ganciclovir intravitreal injection 

 Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • This is an unlicensed special and restricted to Ophthalmology
05.03.02.02 Ganciclovir IV 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to HIV; Haematology; Oncology; Liver and Renal Transplants; Other immunosuppressed patients
    • Virology approval required for all other indications
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Check with Microbiology
05.03.02.02 Ganciclovir oral 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Check with Microbiology
01.01.02 Gastrocote® 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.01.02 Gaviscon Advance® suspension 

Secondary care notes

  • NMUH approvals:
    • Gaviscon Advance Tablets are non-formulary and will not be stocked
    • Gaviscon Advance suspension is formulary
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Suspension only available
01.01.02 Gaviscon Infant® 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Gefitinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team ONLY.
    • See links below
  • RFL approvals:
    • Approved for non-small cell lung cancer
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to the treatment of NSCLC with EGFR mutation.
09.02.02.02 Gelatin intravenous infusion Geloplasma®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.02.02.02 Gelatin intravenous infusion Gelofusine®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.02.02.02 Gelatin intravenous infusion Volplex®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.03 Gemcitabine 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA389 NOT APPLICABLE TO TRUST AS SERVICE IS NOT PROVIDED
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.01 Gemcitabine + oxaliplatin 

Gemcitabine + oxaliplatin for biliary tract cancer where cisplatin is contraindicated
Approved under evaluation at RFL only (July 2014)

07.01.01 Gemeprost 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
02.12 Gemfibrozil 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.03.01 Gentamicin 0.3% drops Ophthalmic

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.01.01 Gentamicin 0.3% drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.03.01 Gentamicin Forte 1.5% eye drops 

Secondary care notes

  • NMUH approvals:
    •  Not applicable
  • RFL approvals:
    •  Not applicable
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available 
    • These are unlicensed specials and restricted to Ophthalmology.
05.01.04 Gentamicin injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • See link below
  • RNOH approvals
    • Different brands of gentamicin 80mg in 2mL vials are stocked at RNOH
    • The Amdipharm, Hospira and Sanofi brands are licensed for administration intramuscularly (IM) and intravenously (IV) and will be kept as stock in all ward areas.
    • The Wockhardt brand is licensed for intravenous route (IV) only and will be stocked in Theatres only. This formulation must not be administered intramuscularly.
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.05 Glandosane® oral spray 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Glandosane may be prescribed by an accredited Speech and Language Therapist.
08.02.04 Glatiramer acetate 

Approve for relapsing-remitting multiple sclerosis inline with NHS England Commissioning (JFC Feb 2016).

Brabio® is the preferred brand.

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Prior funding approval required
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • For relapsing-remitting multiple sclerosis, see above
05.03.03.02 Glecaprevir + Pibrentasvir 

Secondary care notes

  • NMUH approvals:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.02.01 Glibenclamide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Glibenclamide can cause profound hypoglycaemia, especially in the elderly
06.01.02.01 Gliclazide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Gliclazide has been reported to cause less weight gain than other Sulphonylureas.
    • Tolbutamide and Gliclazide are the drugs of choice in renal impairment.
    • Tolbutamide is short acting. Gliclazide is longer acting and is principally metabolised and inactivated in the liver.
06.01.02.01 Glimepiride 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Glimepiride is available for supply on consultant signature only, for the treatment of overweight Type II diabetics, or those with compliance problems.
06.01.02.01 Glipizide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to the diabetes team.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.04 Glucagon GlucaGen® HypoKit

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH approvals:
  • WH approvals:
    • Nil
A2.07 Glucose 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.04 Glucose gel 40% GlucoGel®, Glucoboost®

Secondary care notes

  • NMUH approvals:
    • Glucoboost is stocked at NMUH
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.02.02.01 Glucose Intravenous 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Glucose 5% (100 mL, 250 mL, 500 mL and 1000 mL)
    • Glucose 10% (500 mL)
    • Glucose 20% (500 mL)
    • Glucose 50% (50 mL)
    • Glucose 1% in compound sodium lactate (Hartmann's) (1000 mL)
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.06 Glucose urine test strip Diastix®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.07 Glutaraldehyde 10% solution Glutarol®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.02 Glycerol (Glycerin) 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • See link below
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Suppositories 1 g, 2 g, 4 g
11.99.99.99 Glycerol eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • This is unlicensed and restricted to Ophthalmology
02.06.01 Glyceryl trinitrate parenteral 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
01.07.04 Glyceryl Trinitrate rectal ointment 

Secondary care notes

  • NMUH approvals:
    • Rectogesic brand
  • RFL approvals:
    • Rectogesic brand
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Rectogesic brand is first choice for anal fissures (4mg/g)
02.06.01 Glyceryl trinitrate short-acting (tablets and sprays) 

Secondary care notes

  • NMUH approvals:
    • Nitrolingual Pumpspray and 500mcg sublingual tablets available
  • RFL approvals:
    • Only 500 microgram tablets and 400 microgram spray kept at the RFH.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Sublingual tablets 500 micrograms and 400 microgram spray available at WH
02.06.01 Glyceryl trinitrate transdermal 

Secondary care notes

  • NMUH approvals:
    • Restricted to venous cannulation use only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.04.04 Glycine 1.5% Irrigation Solution 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Available as 3000 mL bags
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.03 Glycopyrronium 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
01.05.03 Golimumab 

See NCL treatment pathway for place in therapy (note: biosimilar adalimumab and biosimilar infliximab are preferred anti-TNFs; JFC April 2019).

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update.
    • See links below.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Consultant Gastroenterologists
    • NICE TA329 applies
10.01.03 Golimumab 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Restricted to Rheumatology
  • RNOH approvals:
    • Rheumatology Consultants ONLY.
  • UCLH approvals:
  • WH approvals
    • As per NICE TA and above
06.05.01 Gonadorelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07.02 Goserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.02 Goserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.02 Goserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Goserelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Goserelin is reserved for the treatment of breast cancer only
A5.02.04 Granuflex 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 20 cm * 20 cm (5) &amp; Border dressing 10 cm * 13 cm (5), 15 cm * 15 cm (5) only
A5.02.01 GranuGel 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.02 Grass and Tree Pollen Extract Pollinex®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
    • Approved for grass/tree-pollen seasonal allergic rhinitis requiring treatment with subcutaneous immunotherapy; restricted to RLHIM/RNTNE allergy clinics for patients experiencing adverse reactions to the allum content of Allergovit  and UCLH paediatric allergy clinics as first line (UCLH only; JFC November 2018)
  • WH approvals:
    • Not Applicable
05.02 Griseofulvin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.02 Griseofulvin 400mcg/spray Grisol AF®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.03 Guanethidine monosulphate 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.08.02 Haem Arginate Normosang®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
20 Haemophilus influenzae type B Combined Vaccine Menitorix®

Approved as Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH approvals:
    • Not applicable
01.07.01 Haemorrhoid relief ointment 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Generic 'Haemorrhoid relief ointment' and Anusol HC available
  • UCLH approvals:
  • WH approvals:
    • Anusol
04.02.01 Haloperidol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Nil  
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.02 Haloperidol depot injection Haldol Decanoate®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
01.03 Helicobacter Test INFAI 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.01 Heparin calcium 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08.01 Heparin sodium 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • See links below
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.08.01 Heparin sodium flush (10 units / mL) 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Nil
13.13 Heparinoid 0.3% Hirudoid®

Secondary care notes

  • NMUH approvals:
    • Cream is formualry and gel is non-formulary
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
14.04 Hepatitis A vaccine Single Component Avaxim®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
14.04 Hepatitis A vaccine Single Component Havrix Monodose®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
14.05.02 Hepatitis B immunoglobulin for intramuscular use 

Secondary care notes

  • NMUH approvals:
    • Available from Health Protection Agency
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Available from Microbiology (Ext 5084)
14.04 Hepatitis B vaccine Single Component Engerix B®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Hepatitis B vaccine Single Component HBvaxPRO®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
14.04 Hepatyrix® Hepatitis A vaccine with typhoid vaccine

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.10.05 Histoacryl® 

Secondary care notes

  • NMUH approvals:
    • Restricted for use by Gastroenterology Consultants.
  • RFL approvals:
    • Cleared for A+E
    • Available for use at Queen Mary's house
    • Restricted prescribing
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.05 Homatropine 1% eye drops 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.05 Homatropine 1% eye drops - preservative free 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Preservative free Eye-drops Eye-drops 1% (Moorfields’ special)
06.05.01 Human Menopausal Gonadotrophins Menogon®

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil

 

21.01 Human normal immunoglobulin 

Subcutaneous immunoglobulin for Multifocal Motor Neuropathy and Chronic inflammatory demyelinating polyradiculoneuropathy
One-year evaluation at UCLH only (October 2014)

21.01 Human papillomavirus vaccine Gardasil®

Guardasil (HPV) vaccine for recalcitrant warts
5 patient evaluation at RFL site only (March 2013)

21.01 Hyaluronic acid injection Ostenil Plus®

Hyaluronic acid injection (Ostenil Plus) to prevent surgery
Approved under evaluation at RNOH only (July 2014)

RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit

10.03.01 Hyaluronidase 

JFC approved for epidurolysis (epidural lysis of adhesions, adhesiolysis) for the treatment of chronic pain in patients presenting with radicular pain (JFC October 2016)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.01 Hydralazine 

 Primary care notes

GP-Red Red Hydralazine injection is for hospital prescribing only

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.02.04 Hydrocoll Border 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.02 Hydrocortisone Colifoam®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone - Topical 

 Secondary care notes

  • NMUH approvals:
    • Hydrocortisone 2.5% Ointment is FORMULARY.
    • Hydrocortisone 2.5% cream is NON-FORMULARY.
    • All other strength are available as both cream and ointment.
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.03.02 Hydrocortisone sodium phosphate Efcortesol®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.03.02 Hydrocortisone sodium succinate Solu-Cortef®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone 0.5% + Nystatin + Benzalkonium + Dimeticone - Topical Timodine®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Non-formulary
    • Store in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Hydrocortisone 1% + Clotrimazole 1% - Topical Canesten HC®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.01.01 Hydrocortisone 1% + Gentamicin 0.3% ear drops Gentisone® HC

Not recommended for acute otitis externa; alternative steroids + aminoglycoside containing drops including Sofradex and Otomize are preferred (JFC March 2018).

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Hydrocortisone 1% + Miconazole 2% - Topical Daktacort®

Secondary care notes

  • NMUH approvals:
    • Datkacort Cream is FORMULARY
    • Daktacort Ointment is NON-FORMULARY
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Store Daktacort cream in the refrigerator 
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone 1% + Nystatin + Chlorhexidine - Topical Nystaform-HC®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only Cream available at the Royal Free Hospital
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone 1% + Urea 10% - Topical Alphaderm®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.02.02 Hydrocortisone acetate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H®

 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.03.01 Hydrocortisone buccal tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.04 Hydrocortisone butyrate - Topical Locoid®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Cream 0.1% 30g, Ointment 0.1% 30g, Lotion 0.1% 30ml ONLY
06.03.02 Hydrocortisone tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
12.03.04 Hydrogen peroxide 6% mouthwash BP 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.11.06 Hydrogen Peroxide Solution BP 

Secondary care notes

  • NMUH approvals:
    • 3% solution stocked at NMUH
    • Check MHRA drug safety updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Solution 3% ONLY
13.02.01.01 Hydromol® bath and shower emollient 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 Hydromol® cream/ointment 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted for the use by Consultant Dermatologists ONLY
    • Ointment 125g, 500g available
04.07.02 Hydromorphone injection 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Relief of severe pain in cancer - intrathecal use for patients on high-dose intrathecal morphine requiring frequent hospital visits for pump refill or unable to tolerate side-effects. Under the National Neuromodulation Registry (UMC Sept 2016)
  • WH approvals:
    • Not applicable
04.07.02 Hydromorphone modified release Palladone® SR

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Haematologists and Consultant Oncologists use only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.02 Hydroxocobalamin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
18 Hydroxocobalamin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Hydroxycarbamide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.01.03 Hydroxycarbamide 

Secondary care notes

  • NMUH approvals:
    • Hydroxycarbamide Suspension 50mg/5ml (100 ml) unlicensed preparation is also available
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Hydroxychloroquine sulfate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted to Rheumatology Consultants Only
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Nil
03.04.01 Hydroxyzine 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Ucerax brand for syrup only
01.02 Hyoscine butylbromide 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety alerts
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Check MHRA drug safety alerts
15.01.03 Hyoscine Hydrobromide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.06 Hyoscine hydrobromide patches 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.06 Hyoscine hydrobromide tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.07 Hypertonic sodium chloride 3% nebuliser solution MucoClear® 3%

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted Item  Restricted for the management of altered respiratory secretions in the spinal injured patient. Requires approval from a member of the Tracheostomy team or an ITU consultant
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.08.01 Hypromellose 0.3% + Dextran 70 0.1% eye drops Tears naturale®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.08.01 Hypromellose eye drops 

Secondary care notes

  • NMUH approvals:
    • 0.3% and 1%
  • RFL approvals:
    • 0.3% only
  • RNOH approvals
    • 0.3%
  • UCLH approvals:
  • WH approvals:
    • 0.3%
11.08.01 Hypromellose eye drops - unit dose 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to ophthalmology
06.06.02 Ibandronic Acid 150mg tablets 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.06.02 Ibandronic Acid 50mg tablets 

Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • 1st line bisphosphonate for the Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
06.06.02 Ibandronic Acid IV injection 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Ibrutinib 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See links below
10.01.01 Ibuprofen 

Secondary care notes

  • NMUH approvals:
    • See MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approvals
    • First choice NSAID
  • UCLH approvals:
  • WH approvals:
    • Intravenous injection restricted to Consultant level
10.03.02 Ibuprofen 5 % gel 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.01.01.01 Ibuprofen IV injection Pedea®
  • NMUH approvals:
    • Refer to SPC
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.02 Idarubicin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.08 Idarucizumab 

For dabigatran reversal. Restricted to patients with who have life/limb threatening bleeding, uncontrolled bleeding, or require emergency surgery (February 2016)

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
    • Kept in blood transfusion lab and restricted to thrombosis haematolgy consultants only
  • WH approvals:
    • Not applicable

 

21.02 Idebenone (free of charge) Raxone®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • EAMS approved for Duchenne’s Muscular Dystrophy for patients in active respiratory decline (%FVCp 80-25%) (UCLH only; September 2018)
  • WH approvals:
    • Not applicable
08.01.05 Idelalisib 

Idelalisib should not be initiated as a first line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.01.01 Ifosfamide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • See link below
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.05.01 Iloprost injection  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • For ITU use only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Available on named patient basis only.  Contact pharmacy for further information
08.01.05 Imatinib tabs 

Gilvec for GIST only.

Generic for all other indications.

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL approvals:
    • Notification only for CML indication Also approved for Ph + ALL (NHSE funded)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA
05.01.02.02 Imipenem + Cilastatin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Microbiology approval only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.03.01 Imipramine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.07 Imiquimod 3.75% cream Zyclara®

Approve for actinic keratosis (AK) and basal cell carcinoma (BCC) (JFC March 2013)

Secondary care notes

  • NMUH approvals:
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second line options (following treatment with fluorouracil): Zyclara for surface area >25cm2, Aldara for surface area <25cm2
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.07 Imiquimod 5% cream Aldara®

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology and GU Consultants
    • Approved for treatment of Superficial basal cell carcinoma, as a second line option, where fluorouracil treatment is contraindicated or has not been tolerated.
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second-line options (following treatment with fluorouracil): Aldara for surface area <25cm2, Zyclara for surface area >25cm2
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Inactivated Influenza Vaccine (Split Virion) 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A5.03.02 Inadine (Povidone-iodine) 

Secondary care notes

  • NMUH approvals:
    • 9.5 x 9.5 cm is stocked at NMUH
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.02.01 Indapamide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.02.01 Indapamide modified release 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Indometacin 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Indometacin Modified Release 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology only
20 Indometacin suppositories 

Approved for tocolytic therapy during pre-natal repair of myelomeningocele, a serious form of spina bifida (UCLH only; JFC February 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • As tocolytic therapy during pre-natal repair of myelomeningocele (fetal spina bifida) (UMC Dec 2017)
  • WH approvals:
    • Not applicable
07.04.01 Indoramin 

Secondary care notes

  • NMUH approvals:
    • Restricted to Urology use only
  • RFL approvals:
    • Restricted to urology only. Only 20mg tablets kept at the RFH.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.11.01 Industrial Methylated Spirit BP 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Infanrix Hexa® Diphtheria, tetanus, pertussis, poliomyelitis (inactivated), hepatitis b (rDNA) and Hib

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Infanrix-IPV+Hib® Diphtheria, Tetanus, Pertussis [Acellular, Component], Poliomyelitis [Inactivated] and Haemophilus T

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.01.03.02 Infatrini 

Secondary care notes

  • NMUH approvals:
    • Infatrini (Nutricia Clinical) Liquid (sip or tube feed) per 100mL
    • For ages 0-12 months to increase calorie intake to meet requirements and for growth.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.03 Infliximab 

Remsima is the preferred brand

 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Restricted to Consultant Gastroenterologists for NICE approved indications
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Consultant Gastroenterologists
    • NICE TA163, TA187 and TA329 applies

 

10.01.03 Infliximab 

Remsima is the brand of choice

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL approvals:
    • Prior funding approval required.
    • Restricted to dermatology, gastroenterology, immunology, neurology, paediatric gastroenterology and rheumatology
  • RNOH approvals:
    • Restricted for Rheumatology Consultants ONLY.
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA and above
13.05.03 Infliximab 

Remcima is the preferred brand

 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Restricted to Consultant Dermatologists 
    • See MHRA Drug Safety Updates
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted
20 Infliximab 

Remsima is the preferred brand.

Approve for steroid-refractory ipilimumab-induced colitis (August 2016)

14.04 Influenza vaccine Enzira®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.01.03 Injection Devices Autopen®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.03 Injection Devices HumaPen® Luxura

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.01 Insulin Humulin® S

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.01 Insulin Actrapid®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.01 Insulin Aspart  NovoRapid®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • For use in accordance with RNOH Hyperglycaemia Protocol for Type 1 Diabetes Mellitus (see link below)
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Insulin degludec Tresiba®

Approved for patients with Type 1 diabetes who had
(i) intermittent adherence to basal insulin leading to recurrent DKA or HbA1c ≥9.5% despite regular intervention from MDT or
(ii) problematic hypoglycaemia and were not eligible for an insulin pump (JFC November 2017)

 

Secondary care notes

  • NMUH approvals:
    • Non formulary
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • As above
06.01.01.02 Insulin Detemir Levemir®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Initiation as per Diabetes team advice
06.01.01.02 Insulin Glargine Lantus®

For continuation only (new starters to use Abasaglar). See NCL guideline for insulin in Type 2 diabetes guideline.

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Alerts
    • See link below
  • RFL approvals:
    • Initiation of therapy under the recommendation of the diabetic team only
    • See link below
  • RNOH approvals:
    • See link below
  • UCLH approvals:
  • WH approvals:
    • As above
06.01.01.02 Insulin Glargine Lantus®

For continuation only (new starters to use Abasaglar). See NCL guideline for insulin in Type 2 diabetes guideline.

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Alerts
  • RFL approvals:
    • Initiation of therapy under the recommendation of the diabetic team only
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • As above
06.01.01.02 Insulin glargine (biosimilar) Abasaglar®

First choice preparation of insulin glargine.

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Alerts
  • RFL approvals:
    • Initiation of therapy under the recommendation of the diabetic team only
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Initiation as per Diabetes team advice
06.01.01.02 Insulin glargine (biosimilar) Abasaglar®

First choice analogue basal insulin. See NCL guideline for insulin in Type 2 diabetes guideline.

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Alerts
    • See link below
  • RFL approvals:
    • Initiation of therapy under the recommendation of the diabetic team only
    • See link below
  • RNOH approvals:
    • See link below
  • UCLH approvals:
  • WH approvals:
    • Initiation as per Diabetes team advice
06.01.01.01 Insulin Lispro Humalog®

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Updates 
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.01 Insulin Lispro 200 units/ml Humalog®
08.02.04 Interferon Alfa IntronA®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Consultant Haematologists and Gastroenterologists only
08.02.04 Interferon Alfa Roferon-A®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Preferred brand for haematology
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.02.04 Interferon gamma-1b Immukin®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Restricted to immunology use only
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
A5.02.01 Intrasite Gel 

Secondary care notes

  • NMUH approvals:
    • 8g stocked only
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.04 Intra-uterine Contraceptive Devices TT 380® Slimline

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.04 Intra-uterine Contraceptive Devices Mini TT 380 Slimline®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.04 Intra-uterine Contraceptive Devices Nova-T® 380

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.04 Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad

Secondary care notes

  • NMUH approvals:
    • Restricted to Obs & Gynae and GU Consultants ONLY
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
07.03.02.03 Intra-uterine levonorgestrel system Levosert®

Approved as first-line intra-uterine device for (JFC March 2018):

  • heavy menstrual bleeding
  • contraception

 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
07.03.02.03 Intra-uterine levonorgestrel system Jaydess®

Not a recommended intra-uterine device for contraception; Kyleena is preferred (JFC February 2019)

Secondary care notes

  • NMUH approvals:
    • Approved for contraception second-line following unsuccessful fitting of Mirena® device (JFC March 2016)
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Approved for contraception second-line following unsuccessful fitting of Mirena® device (March 2016)
07.03.02.03 Intra-uterine levonorgestrel system Mirena®

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.02.03 Intra-uterine levonorgestrel system Kyleena®

Approved as first-line intra-uterine device for contraception (February 2019)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As above
06.02.02 Iodine and Iodide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Ipilimumab 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.02.02 Ipratropium bromide 0.03% nasal spray 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.01.02 Ipratropium pMDI and nebuliser solution 

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • CFC-free inhaler 20 micrograms/metered inhalation ONLY
02.05.05.02 Irbesartan 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to renal patients only.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 1st choice for hypertension / diabetes
08.01.05 Irinotecan Hydrochloride 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • To be prescribed by the Oncology team only.
    • See links below
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.01.01.02 Iron Dextran CosmoFer®

See local guidance for iron replacement

Secondary care notes

  • NMUH approvals:
    • See link below to access the Trust guidelines on use of parenteral irons for iron deficiency anaemia
    • Check MHRA Drug Safety updates
  • RFL approvals:
    • Renal anaemia
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable 
09.01.01.02 Iron Isomaltoside Monofer®

See local guidance for iron replacement

 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety update
  • RFL approvals:
    • Intravenous iron of choice for patients who require rapid iron administration due to capacity issues or certain pathways e.g. pre-op
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.01.02 Iron Sucrose Venofer®

See local guidance for iron replacement

Secondary care notes

  • NMUH approvals:
    • See Trust guidelines on use of parenteral irons for iron deficiency anaemia; link below
    • Check MHRA Drug Safety updates
  • RFL approvals:
    • Renal anaemia
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.03.02 Isocarboxazid 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.02 Isoflurane 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.09 Isoniazid 

Secondary care notes

  • NMUH approvals:
    • Nil (Isoniazid elixir 50mg/5mL [unlicensed] available for the treatment of tuberculosis in children)
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Microbiologist approval only
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Isophane Insulin Insulatard®

Secondary care notes

  • NMUH approvals:
    • The fomulary choices are vial, 3ml cartridge and Innolet.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • First line for patients on a feed or patients that are on high doses of steroids, and require insulin. Available in the EDC Fridge
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.01.02 Isophane Insulin Humulin® I

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Initiation as per Diabetes team advice
02.07.01 Isoprenaline 

Secondary care notes

  • NMUH approvals:
    • For refractory bradycardia. Isoprenaline 2.25mg in 2ml injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Unlicensed Isoprenaline 200 micrograms in 1mL injection is an unlicensed product. Store in a refrigerator.
  • UCLH approvals:
  • WH approvals:
    • Reftractory bradycardia
    • Unlicensed product
02.06.01 Isosorbide dinitrate immediate released 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.06.01 Isosorbide dinitrate parenteral 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to cardiac cath lab use only.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • 0.1% infusion available only
02.06.01 Isosorbide mononitrate 

Secondary care notes

  • NMUH approvals:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
  • RFL approvals:
    • 40mg tablets not stocked in pharmacy
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
13.06.01 Isotretinoin 0.05% + Erythromycin 2% gel Isotrexin®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Isotrexin gel is restricted to Dermatology
13.06.01 Isotretinoin 0.05% gel Isotrex®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.06.02 Isotretinoin capsules 

Secondary care notes

  • NMUH approvals:
    • Restricted to Dermatology
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Isotretinoin capsules are restricted to Dermatology prescribing only and are not available in the community unless by special arrangement, for details see data sheet.
01.06.01 Ispaghula Husk 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.02 Itraconazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Oral preparations restricted to Dermatology; HIV; Haematology; Marlborough OPD
    • Intravenous preparations restricted to Haematology
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
02.06.03 Ivabradine 

See NICE TA for eligibility criteria 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Requires CARDIOLOGIST approval
  • UCLH approvals:
  • WH approvals:
    • Available for prescribing to consultant cardiologists only
    • NICE TA267 applies
13.06 Ivermectin 10 mg/g cream 

Approve for papulopustular rosacea. Suitable for primary and secondary care initiation (JFC July 2016)

Secondary care notes

  • NMUH approvals:
    • To be prescribed by dermatology ONLY for papulopustular rosacea
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • Not applicable
05.05.07 Ivermectin tablets 

Secondary care notes

  • NMUH approvals:
    • 3mg tablets available from 'special order'
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Ixazomib 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.05.03 Ixekizumab injection 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A2.01.01.01 Jevity 

Secondary care notes

  • NMUH approvals:
    • For patients who require a fibre feed, such as those requiring long-term nutrition support.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.01.02.01 Jevity 1.5 kcal 

Secondary care notes

  • NMUH approvals:
    • For patients requiring higher energy intake or fluid restriction or a shorter feeding period who also need a fibre feed.
  • RFL approvals:
    • Nil
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.01.02.02 Jevity Plus 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A2.01.02.02 Jevity Plus HP 

Secondary care notes

  • NMUH approvals:
    • For patients with high protein requirements who need a fibre feed, including those on long-term nutritional support.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
A5.02.06 Kaltostat 

Secondary care notes

  • NMUH approvals:
    • We stock the following in Pharmacy:Kaltostat 7.5x12cm and 5x5cm, Kaltostat Cavity 2g.
    • Kaltostat cavity should only be used when haemostatis is involved. Otherwise Aquacel ribbon (2x45cm) should be used.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Surgical packing 2 g (5)
10.03.02 Kaolin Poultice 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.01.01 Ketamine injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Controlled Drugs Storage and Ordering Requirements
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
21.01 Ketamine oral solution  

Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist)
Evaluation for RFL only (approved by DTC in July-17, ratified by JFC in August-17)

13.10.02 Ketoconazole 2% cream 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatology Outpatients only.
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.09 Ketoconazole 2% shampoo 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatology Outpatients only
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.02.02 Ketoconazole 2% vaginal cream Nizoral®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07 Ketoconazole tablets Ketoconazole HRA®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved as first line in pre-treatment prior to surgery (4-6 weeks prior to surgery) or second line post-surgery in patients with persistent Cushing syndrome (long term treatment)
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
21.01 Ketoconazole tablets 

Ketoconazole for metastatic hormone refractory prostate cancer (third-line and beyond)
Approved under evaluation for 10 patients. RFL only (January 2017)

06.01.06 Ketone urine test strips Ketostix®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For outpatient use only
15.01.04.02 Ketorolac 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to anaesthetists
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Ketorolac tablets are not available
11.08.02 Ketorolac 0.5% eye drops Acular®

Approved for:

  • Treatment of inflammation post cataract surgery in patients unable to tolerate topical corticosteroids
  • Prophylaxis of cystoid macular oedema (CMO) in high-risk patients

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Ophthalmologist use only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
  • UCLH approvals:
  • WH approvals:
    • Restricted to ophthalmology
11.04.02 Ketotifen 250mcg/mL eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.04 Labetalol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.01 Lacosamide  

For patients refractory to standard AEDs (March 2013)

Secondary care notes

  • NMUH approvals:
    • Restricted for neurology patients with refractory epilepsy to standard antiepileptic drugs
  • RFL approvals:
    • Restricted to neurology as second line therapy
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Should only be commenced on the recommendation of a Neurologist only for refractory epilepsy (adjunctive Tx of partial-onset seizures in adults and adolescents)
01.06.04 Lactulose 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.04 Lactulose 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Lamivudine 

Secondary care notes

  • NMUH approvals:
    • Epivir brand only approved for HIV patients
    • Zeffix brand approved for HIV and Hepatitis B patients
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Epivir brand on formulary
04.02.03 Lamotrigine 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
04.08.01 Lamotrigine 

Secondary care notes

  • NMUH approvals:
    • Restricted to Neurology department use only
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Tabs 25 mg, 50 mg, 200 mg. Dispersible tabs 5 mg, 25 mg, 100 mg. Only
08.03.04.03 Lanreotide Somatuline® LA

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to endocrine and neuroendocrine team
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.03 Lanreotide Somatuline Autogel®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to endocrine and neuroendocrine team
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.03.05 Lansoprazole 

Secondary care notes

  • NMUH approvals:
    • See links below
    • Check MHRA Drug Safety Alerts
    • The use of orodispersible tablets is restricted to patients with difficulty in swallowing capsules
  • RFL approvals:
    • Orodispersible tablets restricted to patients with feeding tubes/ difficulty in swallowing tablets
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.02.02 Lanthanum Fosrenol ®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to renal patients only
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01.05 Lapatinib 

Secondary care notes

  • NMUH approvals:
    • Special Funding Approval required - seek advice from Oncology Pharmacist
  • RFL approvals:
    • Approved for breast cancer. Prior funding approval required.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 LAT gel (Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5%) 

Approved for second-line management of pain in children requiring sutures/debridement (JFC February 2018)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Nil
  • WH approvals:
    • Not applicable
11.06 Latanoprost 0.005% + Timolol 0.5% Xalacom®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • Combination therapies to be used when compliance / cost issues arise
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.06 Latanoprost 0.005% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • For ophthalmologists only
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Latanoprost 0.005% eye drops - preservative free 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes

Secondary care notes

  • NMUH approvals:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.03.03.02 Ledipasvir + Sofosbuvir 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Leflunomide 

Secondary care notes

  • NMUH approvals: 
    • Restricted to Rheumatology Consultants ONLY
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology Consultants ONLY
08.02.04 Lenalidomide 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • All prescriptions must be accompanied by a prescription authorisation form
    • See links below
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • As per NICE TA's
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
21.02 Lenalidomide (free of charge) 

Aggressive relapsed / refractory DLBCL as third/last-line option under compassionate use scheme (March 2015)

09.01.06 Lenograstim Granocyte®

Secondary care notes

  • NMUH approvals:
    • Restricted for use in paediatric patients ONLY. For Adult patients, use filgrastim (Zarzio) first line.
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.03.04.01 Letrozole 

Secondary care notes

  • NMUH approvals:
    • Restricted to Oncology department use only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Letrozole 

Approved as a second-line option to induce ovulation in women with WHO group II infertility, following failure of treatment with clomifene citrate (JFC January 2018)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • 2nd line after the failure of clomifene citrate for ovulation induction in women with WHO Group II anovulation
  • WH approvals:
    • As above
06.07.02 Leuprorelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07.02 Leuprorelin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07.02 Leuprorelin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.03.04.02 Leuprorelin Acetate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.01 Levetiracetam 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Neurologists only
    • To be used as second line adjunctive treatment of partial seizures with or without secondary generalisation
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Should only be commenced on the recommendation of a Neurologist
    • Tabs 250 mg, 500 mg, 1 g. Oral solution 100 mg/ 1 ml only
    • Intravenous infusion also available
    • The infusion is available in the emergency drugs cupboard
11.06 Levobunolol 0.5% eye drops 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.06 Levobunolol 0.5% eye drops - unit dose 

See NCL guideline for place in therapy.

Secondary care notes

  • NMUH approvals:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Ophthalmology
15.02 Levobupivacaine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.02 Levobupivacaine + Fentanyl 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.08.01 Levocarnitine 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Paediatric solution not kept at the RFH.
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.12 Levofloxacin 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Microbiologist or Consultant Gastroenterologist recommendation
  • RFL approvals:
    • Restricted to community acquired pneumonia patients with beta-lactam allergy
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
04.02.01 Levomepromazine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Nil  
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.05 Levonorgestrel 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA drug safety updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Levosimendan 

Approved for acutely decompensated severe chronic heart failure who have failed to respond to conventional therapy and failed to respond to or did not tolerate inotropic agents (dobutamine or enoximone) (JFC July 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • As above
06.02.01 Levothyroxine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Oral solution 100 mcg/5ml (adults only) and 50 mcg/5ml available
15.02 Lidocaine + Adrenaline injection Xylocaine®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For emergency caesarean section
12.03.01 Lidocaine 10% spray Xylocaine®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.02 Lidocaine 2% + Chlorhexidine 0.25% gel Instillagel®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
15.02 Lidocaine 2.5% + Prilocaine 2.5% cream EMLA®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
11.07 Lidocaine 4% + Fluorescein 0.25% eye drops - unit dose 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For diagnostic or surgical use only. Not to be given for home use
15.02 Lidocaine 4% cream LMX4®

Approved for topical anaesthetic of first-choice prior to venous cannulation or venepuncture for paediatrics (JFC July 2013)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.02 Lidocaine 4% solution Laryngojet®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Available at the RNTNE only
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
15.02 Lidocaine 5% + Phenylephrine 0.5% topical solution 

Secondary care notes

  • NMUH approvals:
    • Formulary for ENT use only
  • RFL approvals:
    • Available at the RNTNE only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.07.01 Lidocaine 5% ointment 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.02 Lidocaine 5% ointment 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Lidocaine infusion 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Approved for chronic pain only (JFC July 2018)
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • Approved for
      • Chronic pain (RESTRICTED to Pain Management Centre at Cleveland Street for chronic pain; UMC May 2018)
      • Perioperative pain (RESTRICTED to UCH and Westmoreland Street Operating Theatres in line with guideline only; UMC July 2018)
  • WH approvals:
    • Not applicable
02.03.02 Lidocaine injection 

 Secondary care notes

  • NMUH approvals:
    • Ampoules are Formulary but infusions are non formulary.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH:
    • Nil
15.02 Lidocaine injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of lidocaine (lignocaine) 2% cartridge, bupivacaine 0.0625% infusion andropivacaine is restricted to theatres only.
01.06.07 Linaclotide 

Approved for IBS-C in adults where two optimally dosed laxatives (from different classes) and an antispasmodic fail to relieve symptoms. Initiation should be by a Gastroenterologist and reviewed at 4 weeks. Prescribing should be transferred to GPs for ongoing prescribing if found to be effective (JFC May 2017)

Secondary care notes

  • NMUH approvals:
    • To be prescribed as per the JFC recommendations
  • RFL approvals:
    • Not applicable
  • RNOH approval 
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For gastro consultants only as per JFC May 2017 guidance

 

05.01.07 Linezolid 

Secondary care notes

  • NMUH approvals:
    • Microbiology approval only
  • RFL approvals:
    • Microbiology approval required
  • RNOH approvals
    • Microbiology approval only
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
06.02.01 Liothyronine 

Secondary care notes

  • NMUH approvals:
    • Liothyronine injection on formulary
    • Liothyronine tablets may be used for indications other than primary hypothyroidism (e.g. thyroid cancer)
  • RFL approvals:
    • IV only on formulary
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.01.06 Lipegfilgrastim Lonquex®

Alternative to GCSF + district nurse administration at WH only for patients who can receive daily GCSF but cannot self-inject (JFC August 2016)

Secondary care notes

  • NMUH approvals:
    • Not applicable.
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For use by oncology consultants only in patients unable to receive daily GCSF infections or needle phobic patients (D&TC Sept 2016)
13.10.05 LiquiBand® 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.02.01 Liquid and White Soft Paraffin Ointment, NPF 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.03 Liquid Paraffin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.06.04 Liquid paraffin + Magnesium hydroxide oral emulsion, BP 

Secondary care notes

  • NMUH approvals:
    • Restricted to paediatric consultants only
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
11.08.01 Liquid Paraffin and Liquid Paraffin light eye drops Lacrilube®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
A2.04.01.02 Liquigen 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.01.02.03 Liraglutide 

Liraglutide 1.2mg and dulaglutide are the preferred GLP-1RAs for type 2 diabetes, when used in line with the NCL Fact sheet.

Liraglutide 1.8mg is not recommended (JFC July 2018).

Secondary care notes

  • NMUH approvals:
    • See links below
  • RFL approvals:
    • Restricted to endocrinology.
  • RNOH approvals
    • Requires initiation by a Diabetes Specialist
  • UCLH approvals:
  • WH approvals:
    • The use of liraglutide is restricted to Diabetology
02.05.05.01 Lisinopril 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.03 Lithium Carbonate Liskonum®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.02.03 Lithium Carbonate Camcolit®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH approvals:
  • WH approvals:
    • 250mg tablets
04.02.03 Lithium Carbonate Priadel®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH approvals:
  • WH approvals:
    • Nil
04.02.03 Lithium Citrate Li-Liquid®

Secondary care notes

  • NMUH approvals:
    • Lithium Citrate liquid is formulary for those with feeding tubes or swallowing difficulties
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.02.03 Lithium Citrate Priadel® liquid

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Initiate after discussion with liaison psychiatry team.
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
11.04.02 Lodoxamide 0.1% eye drops 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted to Ophthalmology
04.03.01 Lofepramine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.01 Lomustine 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Oncologists and Haematologists use only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.04.02 Loperamide 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Lopinavir + Ritonavir Kaletra®

Secondary care notes

  • NMUH approvals:
    • Check Drug Safety Update
  • RFL approvals:
    • As per HIV guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • For TB / HIV clinic only
03.04.01 Loratadine 

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.01.02 Lorazepam 

 Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • The injection (4 mg in 1mL) must be stored in a refrigerator
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.02 Lorazepam 

Secondary care notes

  • NMUH approvals:
    • First line for status in paediatrics.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.04.01 Lorazepam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Status Epilepticus
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.05.05.02 Losartan 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Alternative (second-line) agent.
    • 25mg and 50mg tablets available only
03.01.05 Low range peak flow meter Mini-Wright®
01.06.07 Lubiprostone 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Restricted Item Restricted
  • UCLH approvals:
  • WH approvals:
    • NICE TA318 applies
05.01.03 Lymecycline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Reserved for Dermatology use only
01.06.04 Macrogols 

Secondary care notes

  • NMUH approvals
    • See link below
    • Movicol stocked
  • RFL approvals:
    • Movicol brand
  • RNOH approval
    • Laxido
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.05 Macrogols Klean-Prep®

Secondary care notes

  • NMUH approvals:
    • For use in renal failure/congestive heart failure only
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  Nil
01.06.05 Macrogols Moviprep®

Approved for bowel evacuation; first-line bowel cleansing agent (Gastroenterology service). 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.06.04 Macrogols paediatric 

Secondary care notes

  • NMUH approvals
    • Restricted to Paediatric Consultants only
    • Movicol Paediatric stocked
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For Paediatrics Only
09.05.01.03 Magnesium Aspartate Magnaspartate®

Approved for magnesium deficiency (JFC March 2017)

Secondary care notes

  • NMUH approvals:
    • See link below to access Trust Formulary bulletin on oral Magnesium Aspartate
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • Second line to NeoMag®
  • WH approvals:
    • First line treatment for hypomagnesaemia (approved by NCL JCF Mar17). Magnesium glycerophosphate only for patients unable to tolerate magnesium aspartate.
01.01.01 Magnesium Carbonate 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.01.03 Magnesium glycerophosphate 4mmol/tablet 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • The BNF states that to prevent recurrence of hypomagnesaemia in adults, oral magnesium may be given in a dose of 24 mmol Mg2+ daily in divided doses. In children aged 1 month to 12 years, the BNF for children recommends that the initial dose of oral magnesium for hypomagnesaemia is 0.2 mmol/kg Mg2+ three times daily, with the dose adjusted as needed. In children aged 12 to 18 years, it recommends that the initial dose is 4 to 8 mmol Mg2+ three times daily, adjusted as needed.
  • UCLH approvals:
  • WH approvals:
    • First line treatment for hypomagnesemia is magnesium aspartate. Magnesium glycerophosphate should only be used for patients unable to tolerate magnesium aspartate.
01.06.04 Magnesium Hydroxide Mixture BP 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.05.01.03 Magnesium Hydroxide Mixture BP  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.05.01.03 Magnesium Sulfate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only magnesium sulphate 50% injection kept at the RFH
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of magnesium sulphate inj 10% & 20% are restricted to Obstetrics only.
13.10.05 Magnesium Sulfate Paste, BP 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
01.01.01 Magnesium trisilicate Mixture BP 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.10.04 Malathion 0.5% liquid Derbac-M®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
03.07 Mannitol inhalation Bronchitol®

Secondary care notes

  • NMUH approvals:
    • Not Applicable
    • This medicine has a positive NICE Technology Appraisal, however, the service not provided at NMUH.
  • RFL approvals:
    • Not Applicable
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
17 Mannitol inhalation  Osmohale®

Approved for for bronchial challenge testing. For diagnostic use in Lung Function Departments (September 2013)

02.02.05 Mannitol IV 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • 10% and 20% (500 mL)
  • UCLH approvals:
  • WH approvals:
    • Nil
05.03.01 Maraviroc 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to use as per London HIV consortium guidelines
  • RNOH approvals
    • Not applicable  
  • UCLH approvals:
  • WH approvals:
    • Not applicable
21.01 Maribavir 

Maribavir for resistant CMV infections
Approved for 3 patients and then to be reviewed at RFL only (January 2015)

A2.04.01.01 Maxijul Super Soluble 

Secondary care notes

  • NMUH approvals:
    • Carbohydrate supplement for use for nutritional support and malnutrition, for those tolerating low volume of food 15g = 60kcals Can be added to moist, liquid foods. Can be used by catering to add to pureed foods, soups, puddings to increase calorie content
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.05.01 Mebendazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
01.02 Mebeverine hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • 135mg immediate release tablets and 200mg MR capsules only
06.04.01.02 Medroxyprogesterone Acetate Provera®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Tabs 5 mg, 10 mg ONLY
08.03.02 Medroxyprogesterone acetate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
07.03.02.02 Medroxyprogesterone acetate 150mg IM injection Depo-Provera®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Depo-Provera is licensed for short and long-term contraceptive use and is given every 12 weeks. Injectable progestogens effectively inhibit ovulation, in addition to effects on the endometrium and cervical mucus
10.01.01 Mefenamic Acid 

Secondary care notes

  • NMUH approvals:
    • Not applicable
    • See link below
  • RFL approvals:
    • Only tablets available at Royal Free Hospital
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.04.01 Mefloquine 

Secondary care notes

  • NMUH approvals:
    • Restricted to HIV patients only
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.03.02 Megestrol acetate 

Secondary care notes

  • NMUH approvals:
    • Restricted to Consultant Oncologists use only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.01.01 Melatonin  

Initiated by the Sleep Disorder Service, second line for up to 13 weeks, after zopiclone, zolpidem, or a benzodiazepine, and prescribing should not be transferred to primary care. (October 2015)

Secondary care notes

  • NMUH approvals:
    • See indication above
  • RFL approvals:
  • RNOH approvals:
    • See indication above
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • Initiation as above only
04.01.01 Melatonin 

Approved for insomnia in learning disability. Specialist initiation and continuation by GP under shared care or fact sheet (October 2016)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • Initiation as above only
04.01.01 Melatonin 

Approved for insomnia in children (> 2 years) with neurological or developmental disorders. Specialist initiation and continuation in primary care (March 2017) Off label use.

Secondary care notes

  • NMUH approvals:
    • See indication above
  • RFL approvals:
    • See indication above
  • RNOH approvals:
    • See indication above
  • UCLH approvals:
  • WH approvals:
    • See indication above
04.01.01 Melatonin  

Approved for:

  • Sleep disorders caused by visual impairment
    • For use by the NHNN Centre for Neuromuscular Diseases for the management of sleep disorders caused by visual impairment. Patients are transferred from GOSH. Appropriate for GPs to continue prescribing. (October 2015)
  • REM Sleep Behaviour Disorder
    • Initiated by the Sleep Disorder Service and can be transferred to primary care once patients have been stabilised. (October 2015) 
  • Circadian Rhythm Disorders
    • Initiated by the Sleep Disorder Service and can be transferred to primary care once patients have been stabilised.  (October 2015) 

Secondary care notes

  • NMUH approvals:
    • See indication above
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • See indication above
  • WH approvals:
    • Initiation as above only
04.01.01 Melatonin Oral Liquid 1mg/1mL 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Restricted for use as a pre-medication in children prior to CT / MRI scan
    • Unlicensed Oral Liquid 1mg/1mL
  • UCLH approvals:
  • WH approvals:
    • For paediatrics only
10.01.01 Meloxicam 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Rheumatology only
08.01.01 Melphalan 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.11 Memantine 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL approvals:
    • Restricted to Mental Health Trust formulary only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.06 Menadiol sodium diphosphate 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • 10 mg tablets stored in the EDC
  • UCLH approvals:
  • WH approvals:
    • Nil
14.04 Meningococcal group B Vaccine Bexsero®

Approved in line with Public Health England Men B immunisation programme  (JFC August 2015) 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
    • Nil
  • WH approvals:
    • Not applicable
14.04 Meningococcal group C conjugate vaccine Menjugate Kit®

Secondary care notes

  • NMUH approvals:
    • Not applicable (however Meningococcal group C conjugate vaccine is listed as being on formulary)
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable (however Meningococcal group C conjugate vaccine is listed as being on formulary)
14.04 Menitorix® Haemophilus type b and Meningococcal group C conjugate vaccine

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.05.01 Menotrophin Merional®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.05.01 Menotrophin Menopur®

Secondary care notes

  • NMUH approvals:
    • First line treatment option for intrauterine insemination. Second line treatment option for ovulation induction in patients in whom clomifene is ineffective.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.04.04 Mepacrine Hydrochloride 

Secondary care notes

  • NMUH approvals:
    • Restricted to Rheumatology Consultants
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
A5.02.03 Mepitel  

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Meptazinol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.03 Mercaptopurine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • For patients intolerant of azathioprine (N.B. dose reduction required if switching from azathioprine)
    • FBC & LFT monitoring required
08.01.03 Mercaptopurine 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.02.02 Meropenem 

Secondary care notes

  • NMUH approvals:
    • Microbiology approval only
  • RFL approvals:
    • Restricted to Neurosurgical meningitis
    • Microbiology approval for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Microbiology approval only
01.05.01 Mesalazine  Mezavant® XL

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Use of mesalazine rectal preparations and the Pentasa & Mezavant brands of mesalazine is restricted to Consultant Gastroenterologists only.
01.05.01 Mesalazine Octasa®

Approved for ulcerative colitis. Octasa is the NCL choice of mesalazine (May 2014, April 2015)

Secondary care notes

  • NMUH approvals:
    • Restricted to Gastroenterologists only
    • Octasa® is the preferred mesalazine preparation at NMUHT.
    • All patients newly initiated on, or requiring dose adjustment of mesalazine, should be prescribed Octasa®.
    • See link below 
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
  • UCLH approvals:
    • Not applicable
  • WH approvals:
    • Octasa® is the preferred mesalazine preparation at WH.  Newly initiated patients on mesalazine should be prescribed Octasa®
01.05.01 Mesalazine Asacol® MR

Secondary care notes

  • NMUH approvals:
    • Restricted Item Restricted: Restricted to Gastroenterologists only
    • Octasa® is the preferred oral mesalazine preparation at NMUHT. All patients newly initiated on, or requiring dose adjustment of mesalazine, should be prescribed Octasa®.
    • See link below  
  • RFL approvals:
    • Octasa® is the preferred oral mesalazine preparation at RFL.  Asacol® is reserved for second line use
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Octasa® is the preferred mesalazine preparation at WH.  Newly initiated patients on mesalazine should be prescribed Octasa®
01.05.01 Mesalazine Pentasa®

Secondary care notes

  • NMUH approvals:
    • Restricted to Gastroenterologists only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted to Consultant Gastroenterologists only
01.05.01 Mesalazine Salofalk®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only rectal preparations are available
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Please note: Rectal foam only
01.05.01 Mesalazine suppositories Asacol®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
08.01 Mesna 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.02.02 Metanium® barrier preparation 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.07.02 Metaraminol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Unlicensed medicine. Available on a named patient basis only.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Metaraminol inj is available for use by anaesthetists only
06.01.06 Meters FreeStyle®
  • NMUH approvals:
    • Optium Neo H meter stocked
  • RFL approvals:
    • Not Applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
06.01.02.02 Metformin 

Secondary care notes

  • NMUH approvals:
    • Nil (metformin liquid is non-formulary)
    • See link below 
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.01.02.02 Metformin 

Approved for patients with Type 1 diabetes with a high BMI who want to achieve weight loss (September 2015)

Secondary care notes

  • NMUH approvals:
    • Nil (metformin liquid is non-formulary)
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Metformin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
    • Nil
  • WH approvals:
    • Not applicable
06.01.02.02 Metformin modified release 

Secondary care notes

  • NMUH approvals:
    • Only to be considered in patients on normal release metformin in whom gastrointestinal side effects prevent continuation of treatment
    • See link below
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Only to be considered in patients on normal release metformin in whom gastrointestinal side effects prevent continuation of treatment
    • See link below
04.07.02 Methadone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.10.03 Methadone 

Secondary care notes

  • NMUH approvals:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
  • RFL approvals:
    • See links below
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Mixture 5 mg/5 ml. Injection 10mg/1ml. Only
03.09.01 Methadone linctus 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • CD = Controlled drug. The Misuse of Drug Regulations apply and all legal requirements need to be met eg outpatient prescriptions and TTAs should state the total amount of drug prescribed in words and figures. For further details see the BNF.
05.01.13 Methenamine Hippurate 

Approved for recurrent UTIs in adults who have experienced ≥ 2 UTIs in the last 6 months, or ≥ 3 in the last 12 months (JFC April 2017)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable  
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.02.02 Methocarbamol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
01.05.03 Methotrexate 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Restricted to gastroenterology
    • 2.5mg tablets must be prescribed for non-malignant indications
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See link below
13.05.03 Methotrexate 

Secondary care notes

  • NMUH approvals:
    •  See link below
  • RFL approvals:
    •  Nil
  • RNOH approvals
    •  Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.03 Methotrexate injection 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Methotrexate injection 

Secondary care notes

  • NMUH approvals:
    • Zlatal is stocked. This is a licensed preparation, but it is not licensed for use in ectopic pregnany
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Methotrexate SC/ IM injection 

The licensed routes of administration for parenteral preparations vary—further information can be found in the product literature for the individual preparations.

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Metoject is not available at RFH. The pharmacy production unit manufactures methotrexate pre-filled syringes for parenteral administration.
  • RNOH approvals:
    • Rheumatology Consultants ONLY
    • Metoject and Nordimet (if autoinjector required) brand
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Nil
03.12 Methotrexate tablets 

Approved for severe asthma. Restricted to the Severe Asthma Service  (September 2015)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.12 Methotrexate tablets 

Approved for sarcoidosis after failure of steroids  (JFC April 2016)

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • See indication above
08.01.03 Methotrexate tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • 10mg tablets restricted for haematology only
  • RNOH approvals
    • Not Appliable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.03 Methotrexate tablets 

Secondary care notes

  • NMUH approvals:
    • See links below.
  • RFL approvals:
    • 10mg tablets restricted for Haematology ONLY
  • RNOH approvals:
    • Restricted for Rheumatology Consultants ONLY
    • 2.5mg tablets ONLY
    • See links below
  • UCLH approvals:
  • WH approvals:
    • Nil
09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

Secondary care notes

  • NMUH approvals:
    • Not applicable.
  • RFL approvals:
    • Restricted to renal team only
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
02.05.02 Methyldopa 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.04 Methylphenidate Hydrochloride Concerta®XL

Approved for ADHD (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to the Child & Adolescent Mental Health Service only
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • As per NICE TA98 / CG87
04.04 Methylphenidate Hydrochloride Equasym®XL

Approved for ADHD (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As above

 

04.04 Methylphenidate Hydrochloride Medikinet®XL

Approved for ADHD (JFC February 2019).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As above
06.03.02 Methylprednisolone acetate Depo-Medrone®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
10.01.02.02 Methylprednisolone acetate Depo-Medrone®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil 
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.02.02 Methylprednisolone acetate + Lidocaine injection Depo-Medrone® with Lidocaine

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil 
  • UCLH approvals:
  • WH approvals:
    • Nil
06.03.02 Methylprednisolone sodium succinate injection Solu-Medrone®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
06.03.02 Methylprednisolone tablets 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Only 2mg and 100mg tablets are formulary
    • 100mg tablets are restricted to neurology use only.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
18 Methylthioninium chloride Proveblue®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
04.06 Metoclopramide 

Secondary care notes

  • NMUH approvals:
    • Check MHRA Safety Drug Updates
  • RFL approvals:
    • Modified release capsules are not stocked at RFH
  • RNOH approvals:
    • Check MHRA Safety Drug Updates
  • UCLH approvals:
  • WH approvals:
    • May induce acute dystonic reactions, especially in children, young adults and the elderly
02.02.01 Metolazone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
02.04 Metoprolol 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Metoprolol injection restricted to cardiology and ITU only.
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.01.11 Metronidazole 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
05.04 Metronidazole 

Secondary care notes

  • NMUH approvals:
    • Not applicable  
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.01.02 Metronidazole 0.75% Anabact®

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.10.01.02 Metronidazole 0.75% 

Brands include Acea®, Metrogel®, Metrosa®, Rosiced®, Rozex®, Zyomet®

Secondary care notes

  • NMUH approvals:
    • Rozex cream is on FORMULARY for use on rosacea only.
    • Rozex gel and all other brands are NON-FORMULARY
  • RFL approvals:
    • Restricted for the treatment of rosacea only
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Metronidazole gel and cream are restricted to Dermatology use only for the treatment of rosacea
07.02.02 Metronidazole 0.75% vaginal gel Zidoval®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
20 Metronidazole ointment 10% 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.03 Metyrapone 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.02 Miconazole 2% - Topical 

Secondary care notes

  • NMUH approvals:
    • Miconazole cream is FORMULARY.
    • Miconazole powder and spray are NON-FORMULARY.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Cream only
  • UCLH approvals:
  • WH approvals:
    • Nil
07.02.02 Miconazole 20mg/g vaginal cream Gyno-Daktarin®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
12.03.02 Miconazole oral gel 

Secondary care notes

  • NMUH approvals:
    • Check for MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.02 Midazolam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.04.01 Midazolam 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Status epilepticus
  • RNOH approvals
    • For paediatric sedation before procedures (including but not limited to MRI and pre-operatively). 
    • UnlicensedUnlicensed - Midazolam 2.5 mg/mL oral solution is an unlicensed product
  • UCLH approvals:
  • WH approvals:
    • Nil
04.08.02 Midazolam Oromucosal Solution Buccolam®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Restricted for use in accordance with Emergency Paediatric Protocol for status epilepticus
  • UCLH approvals:
  • WH approvals:
    • Reserved for the use of Paediatrics only
02.07.02 Midodrine 

Approved for Orthostatic Hypotension for initiation in secondary care by specialist (e.g. Autonomic Unit) and transfer to primary care when stabilised. (July 2015)

Secondary care notes

  • NMUH approvals:
    • To be used only on the recommendation of Consultants experienced in the mangement of severe orthostatic hypotension caused by autonomic dysfunction. Midodrine should only be used if non-pharmacological interventions, such as use of compression stockings, blood pressure monitoring, increased water and salt ingestion have failed. Midodrine is indicated for orthostatic hypotension due to autonomic dysfunctiion ONLY e.g. Parkinson's Disease, diabetic neuropathy. Use in other types of orthostatic hypotension is UNLICENSED. 
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Restricted for use as a second line option for the treatment of symptommatic orthostatic hypotension (JFC 2015)
02.07.02 Midodrine 

Approved for dialysis induced hypotension (off-label). Prescribing to be retained in secondary care.

08.02.04 Mifamurtide 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable to WH
07.01.02 Mifepristone 

Secondary care notes

  • NMUH approvals:
    • Restricted to Obstetrics and Gynaecology Consultants only.
    • Mifepristone must be collected from pharmacy and signed for by a qualified midwife or nurse. 
  • RFL approvals:
    • Restricted to gynaecologist only
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Mifepristone 200 mg tablets are for specialist use only
02.01.02 Milrinone 

Secondary care notes

  • NMUH approvals:
    • Red List Medicine – Hospital Only Prescribing A small amount is kept in the EDC cupboard only.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.03 Minocycline 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Restricted to Dermatology; Marlborough OPD
    • Microbiology approval required for all other indications
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Check with Microbiology
05.01.03 Minocycline modified release 

Secondary care notes

  • NMUH approvals:
    • for Dermatology use ONLY
  • RFL approvals:
    • ???Restricted to Dermatology; Marlborough OPD
    • ???Microbiology approval required for all other indications
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • ???Reserved for Dermatology use only
02.05.01 Minoxidil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Minoxidil is available for the treatment of hypertension resistant to other drugs.  
    • Tablet formulation only
13.09 Minoxidil cutaneous solution 

Secondary care notes

  • NMUH approvals:
    • Regaine Regular Strength topical solution is FORMULARY.
    • Regaine Extra Strength topical solution is NON-FORMULARY.
    • Hospital only - NHS black listed OTC line.
  • RFL approvals:
    • Restricted to Dermatologists.
    • Only the extra strength minoxidil 5% is kept at The Royal Free Hospital.
  • RNOH approval
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
07.04.02 Mirabegron 

See NICE TA and JFC guidance for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Update
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.03.04 Mirtazapine 

Secondary care notes

  • NMUH approvals:
    • See link below
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Restricted for initiation by a Consultant Psychiatrist only
01.03.04 Misoprostol Cytotec®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Tabs 200 micrograms
08.01.02 Mitomycin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.01.05 Mitotane 

Approved for metastatic adrenocortical carcinoma (JFC February 2018)

Secondary care notes

  • NMUH approvals:
    • Not Applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not Applicable
  • UCLH approvals:
  • WH approvals:
    • Not Applicable
08.01.02 Mitoxantrone 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
15.01.05 Mivacurium 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • The use of mivacurium is restricted to theatres only
14.04 MMRvaxPro® Measles, Mumps and Rubella Vaccine, Live (MMR)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable (but MMR vaccine is flagged as on formulary)
04.03.02 Moclobemide 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
04.04 Modafinil 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable  
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    •  As per NICE TA98 / CG87
A2.03.02 Modulen IBD 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
13.04 Mometasone furoate 0.1% - Topical 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Mometasone is restricted to Dermatology use only
    • Cream 0.1% 30g, Ointment 0.1% 30g ONLY
12.02.01 Mometasone furoate 50mcg/spray nasal spray 

Secondary care notes

  • NMUH approvals:
    • To be used as second-line after beclometasone
  • RFL approvals:
    • Nil
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of Mometasone nasal spray is restricted to ENT department only
03.02 Mometasone furoate inhaler Asmanex®

 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to Thoracic Medicine only.
  • RNOH approval
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
03.03.02 Montelukast 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Monteleukast is licensed in adults and children aged six years and over as an add-on therapy for patients with mild to moderate persistent asthma, who are inadequately controlled on inhaled corticosteroids and in whom as needed short acting beta-agonists provide inadequate control of asthma. Or to prevent exercise induced bronchoconstriction. Monteleukast will be prescribed only against a prescription signed by a consultant respiratory physician or paediatrician
04.07.02 Morphine immediate release oral 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Oral solution available as 10 mg/5mL
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Morphine injection 

Secondary care notes

  • NMUH approvals:
    • Nil
    • Unlicensed Morphine Sulfate 1mg in 1ml Injection (10ml vial), available from ‘special-order’ manufacturers or specialist importing companies for sedation and analgesia in paediatric patients. 
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Unlicensed Morphine sulfate 40 mg in 1mL ampoule is an unlicensed product
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Morphine modified release oral 

Secondary care notes

  • NMUH approvals:
    • Morphgesic® SR: 10mg, 30mg, 60mg and 100mg Strengths available. Morphgesic SR is equivalent to Morphine Sulphate SR Continus (MST).
    • MST Continus®: ONLY 5mg MST Continus Tablets and 20mg & 30mg MST Continus Sachets are formulary.
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
04.07.02 Morphine suppositories 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Only the 10mg suppositories are kept at the RFH
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
05.01.12 Moxifloxacin 

Secondary care notes

  • NMUH approvals:
    • Restricted to microbiology and respiratory consultants
  • RFL approvals:
    • Restricted to thoracic medicine
    • ID/Microbiology approval required for all other indications
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • For restricted indications as per Trust guidelines or Microbiology advice
02.05.02 Moxonidine 

Secondary care notes

  • NMUH approvals:
    • Consultant Cardiologist use only
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Not applicable
09.06.07 Multivitamin  

Approved for vitamin deficiency in chronic kidney disease (April 2015)

Secondary care notes

  • NMUH approvals:
    • For continuation of treatment. Initiation by the renal team ONLY.
  • RFL approvals:
    • Not applicable
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.07 Multivitamin preparations Abidec®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Discharge prescribing for neonates only
09.06.07 Multivitamin preparations Dalivit®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
13.10.01.01 Mupirocin 2% Bactroban®

Secondary care notes

  • NMUH approvals:
    • Refer to Trust MRSA eradication protocol
  • RFL approvals:
    • Restricted to Dermatology outpatients for impetigo only
    • Maximum 14 days prescription
    • Only the ointment is kept at The Royal Free Hospital
    • See mupirocin nasal ointment monograph
  • RNOH approval
    • Nil
  • UCLH approvals:
  • WH approvals:
    • The use of Mupirocin ointment is restricted to Microbiology approval only
12.02.03 Mupirocin 2% in White Soft Paraffin nasal ointment Bactroban Nasal®

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • MRSA screening procedure
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
09.06.07 Mutivitamin 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Nil
  • UCLH approvals:
  • WH approvals:
    • Nil
01.05.03 Mycophenolate mofetil 

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Mycophenolate is approved for treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s Disease (CD) in patients with active disease who have failed to respond to Azathioprine/ 6-Mercaptopurine, Methotrexate or biological therapy, and are not for surgery
    • Tabs 500mg
03.12 Mycophenolate mofetil 

Approved for Interstitial lung disease (Connective tissue disease, Hypersensitivity Pneumonitis and Idiopathic Non-specific Interstitial Pneumonia) (JFC April 2016).

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
08.02.01 Mycophenolate mofetil 

Generic and branded preparations are considered bioequivalent but it may be prudent not to change formulation except on the advice of a transplant specialist. 

See NICE TA for eligibility criteria

Secondary care notes

  • NMUH approvals:
    • To be used for continuation of immunosuppressant therapy only
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Mycophenolate is approved for Dr Woolfson's use
    • Tabs 500mg
08.02.01 Mycophenolate mofetil 

Secondary care notes

  • NMUH approvals:
  • RFL approvals:
  • RNOH approvals:
    • Restricted Item Restricted Rheumatology Consultants Only
  • UCLH approvals:
  • WH approvals:
20 Mycophenolate mofetil 

Approved for immunobullous diseases including Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP) and Oral lichen planus (OLP) (JFC, June 2017)

Secondary care notes

  • NMUH approvals:
    • Nil
  • RFL approvals:
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
    • Nil
  • WH approvals:
20 Mydricaine 

Secondary care notes

  • NMUH approvals:
    • For rapid mydriasis and prevention of synechiae in uveitis.
    • Mydricaine No.1 and No.2 Injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • MYDRICAINE NO. 2 This is an unlicensed special and restricted to Ophthalmology.
    • MYDRICAINE NO.1 This is an unlicensed special and restricted to Ophthalmology.
04.06 Nabilone 

Secondary care notes

  • NMUH approvals:
    • Restricted for use in oncology only
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
10.01.01 Nabumetone 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Restricted to Rheumatology and Haematology.
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
06.07.02 Nafarelin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
06.07.02 Nafarelin 

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
02.06.04 Naftidrofuryl oxalate 

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL approvals:
    • Nil
  • RNOH approvals
    • Nil
  • UCLH approvals:
  • WH approvals:
    • NICE TA223 applies